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Abstract	  
	  Histone	  deacetylases	   (HDACs)	  are	  a	  class	  of	  modification	  enzymes	   that	  catalyze	   the	  removal	  of	  acetyl	  molecules	  from	  histone	  and	  non-­‐histone	  substrates.	  Therefore,	  they	  play	  important	  roles	  in	  chromatin	  remodelling	  and	  gene	  expression	  control	  through	  regulation	  of	  histones,	  transcription	  factors,	  and	  chromatin-­‐modifying	  enzymes.	  Class	  I	  HDACs,	  in	  particular	  HDAC1	  and	  HDAC2,	  are	  ubiquitously	  expressed	  and	  are	  critical	  regulators	  of	   cell	   cycle	  progression,	   cellular	  proliferation	  and	  differentiation	  during	  development.	   Besides	   their	   subcellular	   localization	   and	   incorporation	   into	   multi-­‐0subunit	  complexes,	  HDAC1	  and	  HDAC2	  can	  also	  be	  regulated	  by	  a	  plethora	  of	  post-­‐translational	  modifications	  (PTM),	  which	  represent	  a	  complex	  “code”	  that	  modulates	  their	  catalytic	  activity,	   localization	  and	  complex	  assembly.	  Among	  the	  various	  PTMs	  that	   occur	   on	   HDAC1	   and	   HDAC2	   we	   identified	   a	   new	   mitotic-­‐specific	  phosphorylation	  of	  the	  two	  enzymes	  driven	  by	  Aurora	  kinases	  A	  and	  B.	  By	  means	  of	  mammalian	  cells	   and	  zebrafish	  embryos,	  we	  dissected	   the	  biological	   role	  of	  HDAC1	  Aurora-­‐dependent	  phosphorylation	  during	  development,	  contributing	  to	  deciphering	  the	   PTM	   code	   of	   these	   deacetylases.	   Indeed,	   we	   demonstrated	   that	   this	  phosphorylation	   in	   vitro	   and	   in	   vivo	   partially	   and	   dynamically	   affects	   HDAC1	  enzymatic	   activity.	   Moreover,	   we	   found	   that	   Aurora-­‐driven	   phosphorylation	   of	  HDAC1	   is	   critical	   for	   the	  maintenance	   of	   a	   proper	   proliferative	   and	   developmental	  plan	  in	  a	  complex	  organism	  and	  crucially	  regulates	  global	  histone	  acetylation	  levels	  in	  zebrafish	  development.	  	  Thus,	  affecting	  its	  activity	  on	  histone	  acetylation,	  HDAC1	  mitotic	  phosphorylation	  acts	  as	   fine-­‐tune	   regulator	   of	   proper	   cell	   cycle	  progression,	   probably	  by	  modulating	   the	  expression	  of	  genes	  directly	  involved	  in	  zebrafish	  development.	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Introduction	  
Histone	  deacetylases	  and	  the	  regulation	  of	  the	  acetylome	  
Histone	  deacetylases	  (HDACs)	  are	  a	  class	  of	  modification	  enzymes	   that	  regulate	   the	  activity	   of	   their	   substrates	   by	   removing	   acetyl	   groups	   from	   lysine	   residues	   [1,2].	  Histone	  deacetylases	  are	  so	  named	  based	  on	  their	  ability	  to	  deacetylate	  histone	  tails	  and	   promote	   chromatin	   compaction,	   which	   is	   associated	   with	   repression	   of	   gene	  transcription	   [3].	   Alternatively,	   histone	   acetyltransferases	   (HATs),	   promote	   the	  acetylation	  of	  histone	  tails	  hence	   increasing	  the	  accessibility	  of	  DNA	  by	  relaxing	  the	  chromatin	   structure.	   Therefore	   they	   are	   considered	   transcription	   activators	   [4].	   In	  addition	  to	  histones,	  a	  growing	  number	  of	  non-­‐histone	  proteins	  has	  been	  identified	  as	  HDAC	   substrates	   [5],	   suggesting	   that	   these	   enzymes	  may	   be	   involved	   in	   a	   range	   of	  cellular	  processes	  beyond	  the	  regulation	  of	  gene	  expression	  [6].	  	  
The	  histone	  deacetylase	  families	  HDACs	  are	  members	  of	  an	  ancient	  enzyme	  family	  found	  in	  plants,	  animal	  and	  fungi,	  as	  well	   as	   in	   Archeabacteria	   and	   Eubacteria	   [2].	   The	  mammalian	   genome	   encodes	   18	  enzymes	  with	  deacetylase	  activity,	  which	  can	  be	  grouped	  into	  two	  families	  according	  to	  their	  mechanisms	  of	  catalysis:	  the	  classical	  HDAC	  family,	  whose	  members	  are	  zinc-­‐dependent	   deacetylases,	   and	   the	   Sirtuin	   family	   of	   NAD+-­‐dependent	   enzymes	   [7,8].	  Another	   criterion	   of	   classification,	   based	   on	   phylogenetic	   analysis	   and	   sequence	  homology	   to	   the	   corresponding	   Saccharomyces	   cerevisiae	   proteins,	   divides	   HDACs	  into	   four	   classes	   (Figure	  1)	   [2,9,10]:	   Class	   I	   comprises	  HDAC1,	  HDAC2,	  HDAC3	   and	  HDAC8,	  that	  are	  closely	  related	  to	  the	  yeast	  transcriptional	  regulator	  Rpd3	  (Reduced	  potassium	  dependency	   3) and	   are	   expressed	   in	   a	  wide	   range	   of	   cell	   types.	   Class	   II	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includes	  HDACs	  homologous	  to	  the	  yeast	  Hda1	  (Histone	  Deacetylase	  1)	  protein,	  and	  is	  further	  divided	  into	  two	  subclasses:	  class	  IIa	  (HDAC4,	  HDAC5,	  HDAC7	  and	  HDAC9)	  and	   class	   IIb	   (HDAC6	   and	  HDAC10)	   [8].	   Class	   II	   HDACs	   have	   a	   variety	   of	   different	  roles	  in	  muscle,	  heart	  and	  bone	  development	  and	  physiology	  and	  are	  expressed	  in	  a	  tissue	   specific	   manner	   [11].	   Class	   III	   corresponds	   to	   the	   NAD+-­‐dependent	   Sirtuin	  family	   and	   is	   composed	  of	   seven	  members,	   Sirt1-­‐7	   [7];	   they	  are	  homologous	   to	   the	  yeast	  protein	  Sir2	  (Silencing	  Information	  regulator	  2)	  and	  it	  has	  been	  reported	  to	  be	  involved	   in	   genome	   stability	   and	   in	   several	   metabolic	   pathways	   [12].	   The	   only	  member	   so	   far	   belonging	   to	   Class	   IV	   is	   HDAC11,	   which	   is	   a	   zinc-­‐dependent	  deacetylase	   sharing	   common	   features	   with	   both	   class	   I	   and	   class	   II	   HDACs	   [13].	  HDAC11	  was	  shown	  to	  regulate	  the	  balance	  between	  immune	  activation	  and	  immune	  tolerance	  in	  CD4+	  T-­‐cell	  [14]	  and	  to	  play	  a	  role	  in	  oligodendrocyte	  differentiation	  [15].	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  1.	  Classification	  and	  general	  biological	  roles	  of	  mammalian	  histone	  deacetylases	  Classification	  of	  yeast	  and	  mammalian	  HDACs	  according	  to	  their	  mechanism	  of	  catalysis	  and	  sequence	  homology	  are	  schematically	  reported.	  General	  biological	  roles	  for	  each	  class	  are	  also	  indicated.	  


















Class	  I	  HDACs:	  domain	  organization	  and	  function	  Class	   I	   HDACs	   are	   ubiquitously	   expressed	   in	   a	   wide	   range	   of	   tissues	   suggesting	   a	  general	   role	   in	   transcription	   repression.	   Furthermore,	   class	   I	   HDACs	   interact	   with	  many	   lineage-­‐specific	   transcription	   factors	   suggesting	   that	   these	  enzymes	  may	  play	  an	  important	  role	  in	  controlling	  specific	  transcriptional	  programs	  [16].	  	  Class	  I	  HDACs	  display	  a	  modular	  organization	  (Figure	  2):	  a	  well-­‐conserved	  N-­‐terminal	  domain	  that	  represents	  the	  two-­‐thirds	  of	  the	  protein	  and	  covers	  the	  catalytic	  domain	  and	  a	  most	  variable	  C-­‐terminal	  portion.	  The	  N-­‐terminus	  of	  HDAC1	  also	  harbours	  the	  HDAC	   association	   domain	   (HAD)	   that	   mediates	   homo/hetero-­‐dimerization	   with	  HDAC1	   or	   HDAC2.	   The	   two	   proteins	   differ	   from	   each	   other	   in	   their	   C-­‐termini:	   a	  nuclear	  localization	  signal	  (NLS)	  is	  located	  in	  the	  C-­‐terminus	  domain	  of	  HDAC1	  [17],	  whereas	   a	   coiled-­‐coil	   domain	   for	   protein	   interaction	   is	   present	   in	  HDAC2	   [2].	   Both	  HDAC1	  and	  HDAC2	  are	  usually	   localized	   to	   the	  nucleus.	  HDAC1	  and	  HDAC2	  exhibit	  86%	   amino	   acid	   sequence	   identity,	   suggesting	   that	   their	   genes	   were	   probably	  generated	   from	   a	   duplication	   event	   [18,19].	   HDAC1	   and	   HDAC2	   are	   highly	   related	  proteins,	   they	   play	   crucial	   roles	   in	   development	   and	   physiology,	   especially	   in	   the	  heart	   and	   nervous	   system	   [20],	   as	   well	   as	   in	   cellular	   proliferation,	   cell	   cycle	   and	  apoptosis.	  In	  primary	  mouse	  embryonic	  fibroblasts	  (MEFs),	  simultaneous	  deletion	  of	  HDAC1	   and	   HDAC2	   leads	   to	   strong	   cell	   cycle	   arrest	   in	   G1	   phase	   followed	   by	   up-­‐regulation	  of	  p21	  and	  p57	  [21].	  Moreover,	  siRNA-­‐mediated	  knockdown	  of	  HDAC1	  and	  HDAC2	  in	  different	  human	  tumour	  cell	  lines	  suggests	  that	  the	  requirement	  of	  the	  two	  deacetylases	  for	  the	  proper	  cell	  cycle	  progression	  may	  be	  cell-­‐type	  dependent	  [22].	  	  	  HDAC3	  is	  evolutionarily	  most	  closely	  related	  to	  HDAC8,	  sharing	  an	  overall	  sequence	  identity	  of	  43%.	   In	   addition	   to	   the	  NLS	  domain	  at	   the	  C-­‐terminus,	  HDAC3	  carries	   a	  nuclear	  export	   signal	   (NES)	   that	  enables	   the	  enzyme	   to	   shuttle	   from	   the	  nucleus	   to	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the	   cytoplasm	   [23,24].	  Also	  HDAC8	  has	  a	   cytosolic	   localization.	   Increasing	  evidence	  support	  the	  role	  of	  HDAC3	  in	  cell	  cycle	  regulation	  and	  DNA	  damage	  control,	  as	  well	  as	  in	   spindle	   assembly	   checkpoint	   and	   sister	   chromatid	   cohesion	   [25].	   Conditional	  inactivation	  of	  HDAC3	   leads	   to	  a	  delay	   in	  S	  phase	  during	  cell	   cycle	  progression	  and	  increased	   DNA	   damage	   and	   apoptosis	   [26,27].	   Moreover,	   HDAC3	   controls	   G2-­‐M	  progression	   by	   regulating	   CDK1	   (cyclin	   dependent	   kinase	   1)	   levels	   in	   adult	   neural	  stem	  progenitors	  cells	  [27].	  HDAC3	  was	  shown	  to	  be	  associated	  also	  to	  hepatic	  lipid	  homeostasis	  [28,29]	  and	  smooth	  muscle	  differentiation	  [30,31].	  HDAC8	   plays	   an	   important	   role	   in	   neuroblastoma	   tumorigenesis.	   It	   has	   been	  described	  that	  high	  HDAC8	  expression	  levels	  correlate	  with	  advanced	  stage	  childhood	  neuroblastoma	  and	  that	  HDAC8	  ablation	  in	  neuroblastoma	  cells	  inhibits	  proliferation	  and	   causes	   cell	   cycle	   arrest	   [31].	  HDAC8	  was	   also	   found	   in	   association	  with	  HSP20	  (Heat	   Shock	   Protein	   20)	   and	   involved	   in	   its	   deacetylation	   affecting	   myometrial	  activity	  [32].	  	  Although	   class	   I	   HDACs	   are	   commonly	   known	   as	   co-­‐repressors,	   several	   studies	   in	  recent	   years	   have	   challenged	   this.	   In	   particular,	  HDAC1	   and	  HDAC2	   activity	   can	   be	  associated	  with	  the	  activation	  of	  certain	  genes	  [33,34,35,36,37]	  and	  deletion	  of	  these	  enzymes	   individually	   leads	   to	   deregulation	   of	   a	   limited	   set	   of	   genes,	   indicating	   a	  specific	  function	  of	  class	  I	  HDACs	  in	  transcription	  regulation.	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Figure	  2.	  Alignment	  and	  functional	  domain	  organization	  of	  class	  I	  HDACs	  Protein	   sequences	   of	   all	   class	   I	   HDACs	  were	   aligned	   using	   the	   Clustal	  method.	   The	  HAD	  domain	   is	   depicted	   in	  green,	   the	  catalytic	  domain	   in	   light	  blue	  and	  the	  C-­‐terminal	  domain	   in	  pink.	  The	  conserved	  residues	   involved	   in	  catalysis	  are	  in	  boldface	  type.	  	  (Adapted	  from	  [38])	  
	   	  
Regulation	   of	   class	   I	   HDACs:	   multiprotein	   complexes	   and	   post-­‐
translational	  modification	  (PTMs)	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found	  within	   complex	   components	   [46].	  The	  Sin3A	  complex	   is	   essential	   for	   cellular	  viability:	   depletion	   of	   Sin3a	   affects	   the	   early	   developmental	   pre-­‐implantation	   stage	  and	  at	  the	  cellular	  level	   leads	  to	  deregulation	  of	  genes	  involved	  in	  cell	  cycle	  control,	  DNA	   replication,	   DNA	   repair,	   apoptosis,	   chromatin	  modification	   and	  mitochondrial	  metabolism	   [47].	   The	   NuRD	   (Nucleosome	   Remodeling	   Deacetylase)	   complex	   is	  known	  to	  be	   important	   in	  mouse	  development	   [48].	   It	  has	  been	  recently	  associated	  with	   the	   DNA	   damage	   response	   and	   aging	   [49,50]	   and	   it	   also	   contains	   chromatin-­‐remodelling	  ATPase	  activity.	  The	  REST/CoREST	  complex	  has	  more	  specific	  functions:	  it	   recruits	  HDAC1	  and	  HDAC2	  to	  suppress	   the	   transcription	  of	  neural	  genes	   in	  non-­‐neural	  tissues	  [51,52].	  Recently,	   two	   other	   HDAC1/HDAC2	   containing	   complexes	   were	   characterized:	   the	  NODE	  (Nanog	  and	  Oct4-­‐associated	  deacetylase)	  complex	  present	  in	  embryonic	  stem	  cells	   and	   the	   SHIP	   complex	   that	   have	   specific	   function	   during	   embryogenesis	   [53];	  [54].	   MiDAC	   (Mitotic	   deacetylase)	   is	   a	   novel	   mitosis-­‐specific	   deacetylase	   complex	  identified	  by	  a	  chemoproteomics	  approach	  [55].	  By	  contrast,	  HDAC3	  binds	  exclusively	  to	  the	  co-­‐repressor	  complex	  SMRT	  in	  which	  it	  is	  the	  catalytic	  component.	  Moreover,	  it	  was	  found	  that	  HDAC3	  can	  associate	  with	  class	  II	   HDACs	   and	   that	   the	   interaction	   between	   HDAC3	   and	   HDAC7	   influences	   the	  enzymatic	  activity	  of	  HDAC7	  [56];	  [24].	  So	  far	  HDAC8	  has	  not	  been	  reported	  to	  associate	  in	  macromolecular	  complexes.	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Figure	  3.	  HDAC1/2-­‐containing	  multiprotein	  complexes	  Schematic	   representation	   of	   the	   main	   multiprotein	   complexes	   containing	   HDAC1	   and	   HDAC2.	   In	   the	   NODE	  complex,	   the	   transcription	   factors	  Nanog	  and	  Oct4	   interact	  with	  HDAC1	  and	  HDAC2	  and	  other	  members	  of	   the	  SIN3,	   NuRD,	   CoREST	   and	   SWI/SNF	   complexes.	   The	   cartoon	   does	   not	   report	   the	   physical	   interaction	   of	   the	  subunits.	  (From	  [57])	  	  
The	  class	  I	  HDACs	  PTMs	  code	  	  Besides	  their	  subcellular	  localization	  and	  incorporation	  into	  multi-­‐subunit	  complexes,	  class	   I	   HDACs	   can	   also	   be	   regulated	   by	   post-­‐translational	   modifications	   (PTMs)	  including	   phosphorylation,	   acetylation,	   ubiquitination,	   SUMOylation,	   nitrosylation	  and	   carbonylation	   [58,59]	   (Figure	   4).	   These	  modifications	  modulate	   their	   catalytic	  activity,	  localization	  and	  complex	  assembly	  [60].	  	  
-­‐Phosphorylation	  HDAC1,	   HDAC2	   and	   HDAC3	   can	   be	   phosphorylated	   by	   casein	   kinase	   II	   (CKII).	   The	  CKII-­‐dependent	   phosphorylation	   enhances	   the	   deacetylase	   activity	   and	  transcriptional	   repression	   as	   well	   as	   the	   interaction	   with	   multisubunit	   complex	  partners	   [38,61].	   It	   was	   also	   reported	   that	   CKII-­‐dependent	   phosphorylation	   on	  HDAC1	   is	   constitutive	   throughout	   the	   cell	   cycle,	   but	   dispensable	   for	   its	   intrinsic	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activity	  in	  vitro	  [62].	  In	  addition,	  CKII-­‐mediated	  phosphorylation	  of	  HDAC1/2	  during	  mitosis	   leads	   to	   dissociation	   from	   each	   other	   but	   not	   from	   the	   multiprotein	  complexes	  components	  [63].	  	  Interestingly,	   some	   viruses	   induce	   HDAC1/2	   hyper-­‐phosphorylation	   in	   the	   early	  phase	  of	  infection.	  Both	  the	  US3	  kinase	  from	  human	  Herpes	  Simplex	  Virus	  1	  [64]	  and	  its	   homologue	   ORF66	   kinase	   from	   Varicella	   Zoster	   Virus	   [65]	   induce,	   even	   if	  indirectly,	   hyper-­‐phosphorylation	   of	   HDAC1	   and	   HDAC2.	   Recently,	   also	   the	   non-­‐human	   herpesvirus	   Pseudorabies	   Virus	   (PRV)	   US3	   kinase	   was	   shown	   to	   induce	  phosphorylation	  of	  HDAC2,	   indicating	   a	   conserved	   effect	   of	  many	  herpesviruses	   on	  this	   deacetylase	   [66].	   The	   kinase(s)	   directly	   responsible	   for	   HDAC1	   and	   HDAC2	  phosphorylation	  in	  vivo	  is	  unknown.	  HDAC8	   is	   phosphorylated,	   in	   its	  N-­‐terminal	   domain,	   in	  vitro	   and	   in	  vivo	   by	   protein	  kinase	  A	  (PKA),	  which	  negatively	  impacts	  the	  catalytic	  activity	  [67].	  
-­‐	  Acetylation	  Class	   I	   HDACs	   are	   also	   subjected	   to	   reversible	   acetylation.	   HDAC1	   acetylation	   by	  CREB	   binding	   protein	   (CBP)/p300	   leads	   to	   decreased	   enzymatic	   activity	   [68].	  Although	  five	  of	  the	  six	  acetylable	  lysines	  in	  HDAC1	  are	  conserved	  in	  HDAC2,	  HDAC2	  cannot	   be	   acetylated	   in	   vitro	   due	   to	   the	   lack	   of	   lysine	   432,	   which	   seems	   to	   be	   the	  crucial	   residue	   for	   the	   HDAC1	   acetylation.	   However,	   C-­‐terminal	   tail	   swapping	  experiments	  between	  HDAC1	  and	  HDAC2	  showed	  full	  HDAC2	  acetylation	  due	  to	  the	  substituted	   C-­‐terminal	   region	   originating	   from	   HDAC1	   [69].	   More	   importantly,	   the	  crucial	   role	   of	   the	   C-­‐terminal	   region	   in	   the	   differential	   regulation	   of	   the	   enzymatic	  activity	   of	   the	   two	   enzymes	   suggests	   that	   the	   C-­‐terminal	   domain	   of	   HDAC1	   and	  HDAC2,	  which	  is	  not	  conserved	  in	  the	  more	  divergent	  class	  I	  HDAC3	  and	  HDAC8,	  has	  evolved	  to	  specify	  and	  finely	  tune	  the	  functions	  of	  two	  highly	  related	  proteins	  in	  the	  complex	  networks	  of	  mammalian	  systems	  [2,70].	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Acetylation	  of	  HDAC3	  and	  HDAC8	  has	  not	  yet	  been	  reported.	  
-­‐	  Ubiquitination	  Poly-­‐ubiquitination	   mainly	   targets	   proteins	   for	   degradation	   via	   the	   proteasome	  machinery,	  while	  mono-­‐ubiquitination	  acts	  as	  a	  signal	  for	  different	  biological	  outputs	  [71].	  Both	  HDAC1	  and	  HDAC2	  have	  been	   reported	   to	  be	  poly-­‐ubiquitinated	   in	  vitro	  and	  in	  vivo	  [72,73,74].	  Oh	  and	  colleagues	  published	  that	  the	  CHFR	  (CHeckpoint	  with	  FHA	   and	   RING	   domains)	   ubiquitin	   ligase	   downregulates	   HDAC1	   levels	   by	   directly	  binding	  and	  ubiquitinating	  HDAC1.	  This	   functional	   interaction	  between	  HDAC1	  and	  CHFR	  correlates	  with	  increased	  invasiveness	  and	  metastatic	  potential	  of	  prostate	  and	  breast	   cancer	   cell	   lines	   [75].	   Furthermore,	   selective	  ubiquitination	  and	  depletion	  of	  HDAC1,	  but	  not	  of	  other	  class	  I	  HDACs,	  is	  also	  a	  critical	  step	  in	  the	  pro-­‐inflammation	  response	  activated	  by	  tumour	  necrosis	  factor-­‐α	  (TNFα)	  through	  the	  IKK2	  (inhibitor	  of	  nuclear	  factor	  Kappa	  B	  kinase)	  signaling	  pathway	  [76].	  This	  leads	  to	  a	  complete	  loss	  of	   HDAC1	   occupancy	   at	   the	   promoter	   of	   p21WAF/CIP1	   providing	   evidence	   of	   a	   link	  between	   inflammatory	   signaling	   pathways	   and	   modulation	   of	   chromatin	  transcription	  through	  PTMs	  on	  histone	  deacetylases.	  HDAC2	  is	  specifically	  ubiquitinated	  through	  proteasomal	  degradation	  by	  the	  Ubc8	  E2	  conjugating	  enzyme	  and	  the	  RLIM	  E3	  ligase	  upon	  treatment	  with	  the	  HDACs	  inhibitor	  valproic	  acid	  [73].	  Finally,	  HDAC2	  is	  phosphorylated	  and	  degraded	  by	  the	  proteasome	  in	  bronchial	  cells	  upon	  treatment	  with	  cigarette	  smoke	  [77].	  No	  direct	  evidence	  of	  HDAC3	  and	  HDAC8	  ubiquitination	  has	  been	  reported	  so	  far.	  
-­‐	  Sumoylation	  Two	  SUMOylation	  sites	  of	  HDAC1	  were	  mapped	  on	  lysines	  K444	  and	  K476	  [72,78].	  De	  Pinho’s	  laboratory	  reported	  a	  60%	  reduction	  of	  transcriptional	  repression	  of	  the	  2R	  HDAC1	  mutant,	  even	  if	  the	  binding	  with	  the	  Sin3a	  protein	  was	  unaffected.	  Moreover,	  overexpression	  of	  wild	   type	  HDAC1,	  but	  not	  of	   the	  SUMO-­‐deficient	  mutant,	   induced	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accumulation	   of	   cells	   in	   the	   G2	   phase	   of	   the	   cell	   cycle,	   suggesting	   that	   the	  SUMOylation	   mutant	   of	   HDAC1	   has	   some	   impaired	   biological	   functions	   [72].	  Furthermore,	   other	   studies	   have	   reported	   that	   SUMO	   modification	   promotes	  transcriptional	  repression	  of	  HDAC1/HDAC2	  containing	  complexes,	  such	  as	  Elk1	  (ETS	  domain-­‐containing	   protein	   1)	   or	   Mi-­‐2/NuRD	   [79,80].	   Finally,	   it	   has	   been	  demonstrated	  that	  only	  SUMO1	  and	  not	  SUMO2	  conjugation	  to	  HDAC1	  promotes	   its	  ubiquitination	  and	  degradation	  [81].	   In	  this	  way,	  specific	  SUMO	  paralog	  conjugation	  controls	  HDAC1	  protein	   turnover	   in	  mammalian	   cells.	   It	   is	   also	  worth	  noticing	   that	  SUMOylation	  of	   the	  phospho-­‐null	  mutant	  S421A,	  S423A	  of	  HDAC1	  is	   increased	  with	  respect	   to	   the	  wild	   type	   protein	   [78].	   This	   finding	   suggests	   a	   negative	   relationship	  between	  CKII	  phosphorylation	  and	  SUMOylation.	  No	  data	  are	  available	  in	  literature	  regarding	  the	  other	  class	  I	  HDACs.	  
-­‐	  Nitrosylation	  Tyrosine	  nitration	  was	  observed	   in	  HDAC1,	  HDAC2	  and	  also	  HDAC3	   in	  macrophage	  cells	   after	   exposure	   to	   cigarette	   smoke	  with	   a	   consequent	  down-­‐regulation	  of	   their	  protein	  levels	  [82].	  Interestingly,	  mutation	  in	  the	  tyrosine	  Y253	  of	  HDAC2	  in	  human	  alveolar	   epithelial	   cancer	   cells	   abolished	   the	   proteasomal-­‐dependent	   pathway,	  suggesting	  that	  tyrosine	  nitrosylation	  of	  HDAC2	  is	  a	  stress	  signal	  to	  drive	  specifically	  its	  degradation.	   In	  neurons,	   cysteine	   (S)-­‐nitrosylation	  of	  HDAC2	   leads	   to	   chromatin	  remodeling,	  causing	  the	  release	  of	  HDAC2	  from	  neurotrophin-­‐dependent	  promoters	  and	  thereby	  stimulating	  transcription	  [83].	  S-­‐nitrosylation	  of	  HDAC2	  also	  plays	  a	  role	  in	   the	  pathogenesis	  of	  Duchenne	  muscular	  dystrophy,	  where	   it	   is	   correlated	  with	   a	  decrease	   in	   HDAC2	   enzymatic	   activity	   and	   partial	   rescue	   of	   the	   myotube	  differentiation	   abilities	   of	   cells,	   which	   are	   lost	   in	   the	   pathology	   [84].	   Recent	   work	  showed	   that	  S-­‐nitrosylation	  of	  HDAC2	   in	  macrophages	   following	   lipopolysaccharide	  (LPS)	   stimulation	   affects	   the	   stability	   of	   the	   binding	   between	   HDAC2	   and	   MTA1	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(Metastasis	  associated	  protein	  1),	  with	  consequent	  dissociation	  of	  the	  NuRD	  complex	  from	  chromatin	  and	  activation	  of	   transcription	  of	  some	  inflammatory	  genes	  such	  as	  IL1b	  (interleukine	  1b),	  TNFα	  and	  MIP2	  (macrophase	  inflammatory	  protein	  2)	  [85].	  No	  S-­‐nitrosylation	  has	  been	  reported	  for	  HDAC1	  or	  HDAC3	  [84].	  These	   studies	   suggest	   an	   emerging	   role	   of	   S-­‐nytrosilation	   in	   regulating	   the	  chromatin-­‐associated	  dynamics	  of	  HDAC2,	   in	  a	  very	  specific	  way	  compared	  to	  other	  class	  I	  HDACs,	  such	  as	  the	  highly	  related	  HDAC1.	  	  In	   addition,	   HDAC8	   can	   be	   S-­‐nitrosylated	   in	   vitro,	   which	   reversibly	   inhibits	   its	  enzymatic	  activity	  [28].	  However,	  this	  modification	  on	  HDAC8	  could	  not	  be	  detected	  under	  physiological	  conditions	  in	  vivo	  [60].	  
-­‐	  Carbonylation	  HDAC1,	   HDAC2	   and	  HDAC3,	   but	   not	   HDAC8	   can	   be	   carbonylated.	   Carbonylation	   of	  HDAC1	  does	  not	   impair	   its	   intrinsic	   enzymatic	   activity	   but	   disrupts	   its	   interactions	  with	   binding	   partners	   and	   histone	   substrates	   in	   vivo	   [86].	   As	   a	   consequence,	  increased	   acetylation	   of	   lysine	   9	   of	   histone	   H3	   was	   observed	   with	   concomitant	  transcriptional	   activation	   of	   some	   HDAC1-­‐repressed	   genes,	   such	   as	   HO-­‐1	   (Heme	  oxygenase	  1),	  Gadd45	  (Growth	  arrest	  and	  DNA	  damage	  45)	  and	  HSP70	  (Heat	  shock	  protein	  70).	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Figure	  4.	  HDAC1	  and	  HDAC2	  post-­‐translational	  modifications	  Schematic	  overview	  of	  the	  posttranslational	  modifications	  occurred	  on	  HDAC1	  and	  HDAC2	  C-­‐terminus.	  The	  letters	  and	  the	  numbers	  indicate	  respectively	  the	  residues	  and	  the	  position	  on	  which	  the	  PTM	  occurs.	  (From	  [57])	  
	  	  
Biology	  and	  functions	  of	  class	  I	  HDACs:	  the	  animal	  models	  
Class	  I	  HDACs:	  the	  mouse	  model	  
-­‐Germline	  deletion	  Every	   class	   I	  HDAC	  member	  has	   been	  deleted	   either	   globally	   or	   in	   a	   tissue-­‐specific	  manner	   in	   mouse	  models.	   Germline	   deletion	   of	  Hdac1	   in	   mice	   leads	   to	   embryonic	  lethality	  before	  day	  E10.5	  because	  of	  severe	  developmental	  and	  proliferative	  defects	  as	   well	   as	   growth	   retardation	   [21,87,88].	   Indeed,	   Lagger	   and	   colleagues	  demonstrated	  that	  the	  cyclin-­‐dependent	  kinase	  inhibitor	  p21WAF1/CIP1	  is	  up-­‐regulated	  in	   HDAC1	   knockout	   mice	   and	   in	   HDAC1	   deficient	   embryonic	   stem	   cells	   (ES).	  Moreover,	  deletion	  of	  p21WAF1/CIP1	  in	  HDAC1	  deficient	  ES	  cells,	  but	  not	  in	  HDAC1	  null	  mice,	  is	  able	  to	  rescue	  the	  proliferation	  defects	  [87,89].	  On	  the	  contrary,	  the	  impact	  of	  
Hdac2	   ablation	   in	   mice,	   due	   to	   cardiac	   defects,	   results	   in	   perinatal	   lethality	   [88],	  partial	   perinatal	   lethality	   [90]	   or	   partial	   lethality	   within	   the	   first	   months	   [91,92],	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depending	  on	  the	  distinct	  strategies	  used	  to	  generate	   loss-­‐of-­‐function	  Hdac2	  alleles.	  Globally,	  the	  knockout	  studies	  of	  HDAC1	  and	  2	  underline	  specific	  and	  distinct	  roles	  of	  the	  two	  highly	  homologous	  enzymes.	  Knockout	   of	   HDAC3	   also	   leads	   to	   embryonic	   lethality	   before	   day	   E9.5	   caused	   by	  gastrulation	   defects	   [26,93],	   whereas	   HDAC8	   ablation	   in	   mice	   results	   in	   perinatal	  lethality	  due	  to	  skull	  instability	  [94].	  
-­‐Conditional	  deletion	  Since	  germline	  ablation	  of	  class	   I	  HDACs	  results	   in	  early	  embryonic	   lethality,	   taking	  advantage	   of	   conditional	   cre	   recombinase-­‐mediated	   deletion,	   a	   variety	   of	   tissue-­‐specific	  HDAC	  knockouts	  have	  been	  generated.	  HDAC1	   and	   HDAC2	   are	   usually	   co-­‐expressed	   and	   often	   show	   redundancy	   in	   their	  function	  [21,95,96].	  Thus,	  loss	  of	  either	  HDAC1	  or	  HDAC2	  in	  different	  cell	  lines	  such	  ES	  cells,	  fibroblasts,	  B	  cells,	  keratynocytes,	  cardiomyocytes	  and	  neurons	  exhibit	  only	  mild	   effects	   [21,60,87,95].	   This	   is	   probably	   due	   to	   the	   fact	   that	   in	   most	   of	   these	  cellular	   systems,	   deletion	   of	  Hdac1	   leads	   to	   an	   increased	   HDAC2	   protein	   level	   and	  vice	  versa,	  without	  corresponding	  changes	  in	  the	  mRNA	  levels	  [22];	  Yamaguchi	  et	  al.	  2010;	  Lagger	  et	  al.	  2002;	  Wilting	  et	  al.	  2010).	  This	  compensatory	  effect	  masking	  the	  loss	  of	  the	  other	  paralog,	  hides	  the	  knockout	  phenotype.	  	  Nevertheless,	   knockout	   of	   HDAC1	   in	   T	   cells	   and	   ES	   cells	   results	   respectively	   in	  increased	   airway	   inflammation	   and	   enhanced	   embryoid	   bodies	   differentiation,	  suggesting	  a	  pivotal	  role	  of	  HDAC1	   in	   the	  modulation	  of	   the	   inflammatory	  response	  and	   in	   cell	   fate	   determination	   [97,98].	   Moreover,	   loss	   of	   HDAC1	   correlates	   with	  tumour	  development	  in	  skin	  tumour	  models.	  Evidence	  of	  HDAC1	  acting	  as	  a	  tumour	  suppressor	  also	  in	  T	  and	  B	  cells	  were	  independently	  furnished	  by	  Dovey,	  Heideman	  and	   Santoro	   [99,100,101].	   Conversely,	   several	   reports	   suggest	   a	   role	   for	   HDAC2	   in	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adult	   neuronal	   progenitor	   differentiation	   and	   in	   synaptic	   plasticity	   after	   neuronal	  maturation.	  If	   single	   conditional	   deletion	   of	   HDAC1	   or	   HDAC2	   results	   in	   a	   mild	   phenotype,	  simultaneous	   conditional	   ablation	   of	   the	   two	   enzymes	   leads	   to	   severe	   defects	   in	  proliferation,	   differentiation	   and	   survival	   in	   many	   cell	   types	   and	   tissues.	   Indeed,	  combined	   loss	   of	   HDAC1	   and	   HDAC2	   causes	   cell	   cycle	   arrest	   in	   G1	   phase	   and	   cell	  death	   [21]	   in	   fibroblasts	   and	   B	   cells	   and	   the	   failed	   differentiation	   of	   neuronal	  precursors	  into	  mature	  neurons	  (Montgomery	  et	  al.	  2009).	  Furthermore,	  concomitant	  deletion	  of	  the	  two	  enzymes	  provokes	  de-­‐regulation	  of	  important	  signaling	  pathways	  including	  p53/p63	  pathways	  in	  epidermis	  [96],	  Bmp4	  (Bone	  morphogenetic	  protein	  4)	  and	  Rb1	  (Retinoblastoma	  protein	  1)	  in	  lung	  [102]	  and	  Wnt/ß	  catenin	  pathway	  in	  oligodendrocytes	   [103].	   DNA	   damage	   or	   chromosomal	   abnormalities	   followed	   by	  apoptosis	   in	   cell	   types	   and	   organs	   upon	   dual	   loss	   of	   HDAC1	   and	   HDAC2,	   is	   also	  worthy	  of	  notice	  [4,21,99,100,104].	  Loss	  of	  HDAC3	  or	  HDAC8	  evokes	  a	  strong	  phenotype	  including	  developmental	  defects	  and	   lethality.	   Liver-­‐specific	   deletion	   of	   HDAC3	   correlates	   with	   hepatocellular	  carcinoma	   caused	   by	   DNA	   damage	   and	   genomic	   instability	   [105],	   while	   cardiac-­‐specific	  ablation	  of	  the	  enzyme	  leads	  to	  cardiac	  hypertrophy	  and	  aberrant	  expression	  of	   cardiac	   metabolism	   genes	   [93].	   HDAC3	   also	   negatively	   regulates	   memory	  formation	  [106].	  Finally,	   conditional	   loss	   of	   HDAC8	   in	   neural	   crest	   cells,	   as	   for	   its	   global	   deletion,	  provokes	  skull	  instability	  and	  perinatal	  lethality	  [94].	  	  	  
	  	  
	  24	  
Class	  I	  HDACs:	  the	  zebrafish	  model	  In	   zebrafish,	   class	   I	   HDAC	   consists	   of	   three	   members:	   Hdac1,	   orthologue	   of	   the	  murine	  HDAC1	  and	  HDAC2,	  Hdac3	  and	  Hdac8.	  	  Hdac1	   is	   specifically	   required	   to	   promote	   neuronal	   specification	   in	   the	   developing	  zebrafish	   Central	   Nervous	   System	   (CNS)	   [107,108,109,110].	   Several	   studies	   have	  shown	   that,	   in	   the	   hindbrain,	   Hdac1	   represses	   the	   Notch	   target	   E(spl)-­‐related	  neurogenic	  gene	  her6	  thus	  providing	  expression	  of	  proneural	  genes	  in	  differentiating	  neuronal	  precursors	  [107,108,109,111,112].	  Hdac1	   is	   also	   required	   for	   the	   switch	   from	   proliferation	   to	   differentiation	   in	   the	  zebrafish	  retina	  and	  optic	  stalk.	  It	  promotes	  cell	  cycle	  exit	  by	  antagonizing	  Notch	  and	  Wnt	   signaling	   pathways	   and	   this	   correlates	   with	   repressing	   cyclins	   D1	   and	   E2,	  eliciting	   CDK	   inhibitor	   expression	   and	   triggering	   neural	   progenitors	   cell	   cycle	   exit	  (Yamaguchi	  et	  al.	  2005;	  Stadler	  et	  al.	  2005).	  In	  contrast	  with	  the	  overall	  reduction	  of	  proliferation	   in	  mouse	  HDAC1	  mutant	   embryos,	   due	   to	  decreased	   cyclin-­‐dependent	  kinase	  activity	  [87],	  and	  with	  the	  reduced	  proliferation	  observed	  in	  the	  hindbrain	  of	  zebrafish	   hdac1	   mutants	   [107],	   Yamaguchi	   and	   colleagues	   demonstrated	   that	   in	  zebrafish	  hdac1	  mutants	  retinal	  cells	  fail	  to	  differentiate	  into	  neurons	  and	  glial	  cells	  but	  instead	  continue	  to	  proliferate.	  Taken	  together,	  these	  evidences	  suggest	  that	  Hdac1	  can	  function	  either	  as	  a	  positive	  or	  as	  a	  negative	  regulator	  of	  the	  cell	  cycle,	  depending	  on	  the	  tissue	  and	  the	  cell	  type	  in	  which	  it	  is	  active.	  	  Hdac1	  has	  also	  been	  found	  to	  be	  required	  for	  the	  differentiation	  of	  motoneurons	  from	  ventral	   neural	   progenitors	   upon	   hedgehog	   signaling	   [107],	   for	   normal	   craniofacial	  and	  fin	  development	  in	  zebrafish	  embryos	  [113,114]	  and	  in	  the	  organogenesis	  of	  the	  pancreas	  [115].	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Moreover,	   it	   has	   been	   demonstrated	   that	   Hdac3	   regulates	   zebrafish	   liver	  development	   by	   inhibiting	   growth	   differentiation	   factor	   11	   (gdf11)	   [115].	   Hdac8	  functions	   as	   a	   SMC3	   (Structural	   maintenance	   of	   chromosomes	   3)	   deacetylase	   to	  facilitate	   renewal	   of	   cohesin	   following	   its	   removal	   from	   chromatin	   in	   prophase	   or	  anaphase	  and	   that	   loss	  of	  HDAC8	  activity	  results	   in	  decreased	  cohesion	  at	   localized	  sites	  to	  cause	  both	  cellular	  and	  clinical	  features	  of	  Cornelia	  de	  Lange	  Syndrome	  [116].	  	  
Class	  I	  HDACs	  and	  Cancer	  Since	  class	  I	  HDACs,	  in	  particular	  HDAC1	  and	  HDAC2,	  are	  deeply	  involved	  in	  cell	  cycle	  progression	  and	  proliferation	  [87],	  it	  is	  not	  surprising	  that	  they	  might	  be	  implicated	  in	   aberrant	   pathways	   occuring	   in	   tumoral	   cells	   in	   humans.	   Indeed,	   several	   HDACs	  were	  found	  to	  be	  deregulated	  (overexpressed)	  in	  various	  kinds	  of	  tumour	  or	  cancer	  cell	   lines,	   suggesting	   that	   this	   (de)-­‐regulation	   could	   play	   a	   role	   in	   cancer	  [117,118,119,120].	   Over-­‐expression	   of	   HDAC1	   is	   reported	   for	   breast	   [121],	   gastric	  [117,122],	  pancreatic	  [123,124],	  colorectal	  [125],	  hepatocellular	  [126]	  and	  prostatic	  [119]	   carcinomas.	   HDAC1	   over-­‐expression	   results	   in	   a	   less	   differentiated	   status	   of	  cells,	  enhanced	  proliferation	  and	  invasion,	  and	  to	  more	  advanced	  stage	  diseases	  with	  worse	   prognosis	   [127].	   HDAC2	   plays	   a	   major	   role	   in	   Adenomatous	   polyposis	   coli	  (APC)-­‐colon	  cancer	  and	  its	  over-­‐expression	  is	  present	  already	  at	  the	  early	  polyp	  stage	  [128].	   High	   levels	   of	   HDAC2	   are	   found	   also	   in	   cervical	   dysplasia	   and	   invasive	  carcinomas	   [124].	   HDAC1	   and	   HDAC2,	   together	   with	   HDAC3	   expression	   are	  associated	  with	  poor	  prognosis	  in	  gastric,	  prostate	  and	  colorectal	  cancers	  [122,125].	  	  In	   childhood	   neuroblastoma	   high	   HDAC8	   expression	   is	   associated	   with	   advanced	  stage	  of	  disease	  and	  poor	  prognosis	  [31].	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Histone	  deacetylase	  inhibitors	  (HDACi)	  Given	   the	   involvement	  of	  HDACs	   in	  many	   types	  of	   cancer,	   these	   findings	   sparked	  a	  very	  intense	  interest	  on	  the	  possible	  use	  of	  HDACi	  for	  therapeutic	  purposes.	  Although	  the	  research	  on	  the	  therapeutic	  potential	  of	  HDACi	  was	  initially	  focused	  on	  oncology,	  also	   other	   areas	   such	   as	   neurodegeneration	   or	   autoimmunity	   have	   recently	   been	  investigated.	  HDACi	  can	  be	  grouped	  into	  four	  main	  structural	  classes,	  with	  a	  growing	  list	   of	   novel	   compounds:	   first,	   the	   hydroxamic	   acids	   [e.g.	   trichostatin	   A	   (TSA),	  Suberoylanilide	   Hydroxamic	   Acid	   (SAHA,	   Vorinostat,	   Zolinza®),	   and	   LBH589	  (Panobinostat)];	   second,	   the	   short	   chain	   carboxylic	   acids	   [Phenylbutyrate	   and	  Valproic	   acid	   (VPA)];	   third,	   the	   benzamides	   [MS-­‐275	   (Entinostat)];	   and	   fourth,	   the	  cyclic	   tetrapeptides	   [Romidepsin	   (FK-­‐228	   2,	   Istodax®)].	   They	   all	   target	   the	  deacetylase	   enzymatic	   activity	   of	   HDACs	   by	   binding	   the	   active	   site	   and	   competing	  with	   the	   Zn2+	   ion	   in	   the	   active	   pocket	   [129,130].	   This	   results	   in	   increased	   histone	  acetylation	  following	  the	  blocking	  of	  the	  substrate	  pocket	  and	  the	  inactivation	  of	  the	  enzyme	  [131].	  HDACi	  also	  affects	  biological	  processes	  other	  than	  chromatin	  dynamics	  and	  increases	  the	  acetylation	  level	  of	  non-­‐histone	  proteins,	  such	  as	  tubulin	  and	  others	  [132,133,134].	  A	  common	  effect	  of	  HDACi	   in	  cancer	  cells	   is	   the	   induction	  of	   the	  cell	  cycle	   regulator	   p21	   [135]	   via	   a	   p53-­‐independent	   manner.	   The	   p21	   up-­‐regulation	  represents	   the	   basis	   of	   the	   proliferation-­‐inhibiting	   effects	   of	   HDACi	   in	   cancer	   cells	  [136].	  Pan-­‐HDACi	  cause	  cell	  cycle	  arrest	  and	  inhibit	  proliferation,	  leading	  to	  induction	  of	  differentiation,	  growth	  arrest,	  and	  apoptosis	  of	  transformed	  cells	  [137,138].	  These	  effects	  are	  dose	  and	  inhibitor-­‐dependent.	  	  Several	   HDACi	   have	   been	   investigated	   in	   clinical	   trials	   for	   their	   potential	   as	  anticancer	   drugs	   [136,139].	   The	   first	   identified	   HDACi	   is	   the	   naturally	   occurring	  antifungal	   antibiotic	   TSA	   [117].	   TSA	   is	   one	   of	   the	   most	   potent	   HDACi,	   exerting	   its	  function	   in	   nanomolar	   range	   against	   HDAC1,	   2,	   4,	   6,	   7,	   and	   9,	   but	   less	   efficiently	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against	  HDAC8	  [140].	  Because	  of	  pharmacological	  side	  effects,	  TSA	  was	  not	  suitable	  for	   clinical	   use,	   although	   it	   appeared	   very	   promising	   in	   preclinical	   trials	   [141].	   To	  date,	   three	   HDACi	   have	   been	   approved	   as	   anticancer	   drug	   in	   humans:	   Vorinostat	  (SAHA,	   Zolinza®;	  Merck	   Research	   Laboratories),	   Romidepsin	   (FK-­‐228	   2,	   Istodax®;	  Gloucester	  Pharmaceuticals)	  and	  Belinostat	  (Beleodaq®;	  Spectrum	  Pharmaceuticals).	  SAHA	   has	   been	   approved	   since	   2006	   as	   a	   therapy	   in	   patients	   with	   progressive,	  persistent,	  or	  recurrent	  cutaneous	  T	  cell	  lymphoma	  (CTCL)	  after	  one	  or	  more	  cycles	  of	  chemotherapy	  [142,143,144,145,146].	  SAHA	  efficiently	  inhibits	  HDAC1,	  2,	  3,	  4,	  6,	  7,	  and	   9,	   similarly	   to	   TSA,	   but	   it	   is	   5-­‐	   to	   30-­‐fold	   less	   potent	   [140].	   Conversely,	  Romidepsin	   (FK-­‐228	   2)	   is	   one	   of	   the	  more	   selective	   inhibitors.	   It	   strongly	   inhibits	  HDAC1	   and	   2,	   and	   HDAC	   class	   II	   enzymes	   at	   higher	   concentrations	   [147,148,149].	  Since	   2009	   it	   has	   also	   been	   approved	   to	   treat	   CTCL	   [150].	   Recently,	   Belinostat	  received	   its	   first	   global	   approval	   as	   monotherapy	   for	   relapsed	   or	   refractory	  peripheral	  T-­‐cell	  lymphoma	  (PTCL)	  since	  it	  has	  been	  found	  to	  inhibit	  class	  I,	  II	  and	  IV	  HDACs	  [151].	  The	  major	   side	   effects	   associated	  with	   HDACi	   are	   gastrointestinal	   symptoms,	   bone	  marrow	   suppression,	   cardiac	   toxicity,	   thrombocytopenia,	   neutropenia,	   diarrhea,	  nausea,	  vomiting	  and	   fatigue	   [16].	  Despite	   these	   side	  effects,	   it	   is	   important	   to	   take	  into	  account	   that	  HDACi	  are	  well	   tolerated	  by	   the	  majority	  of	  patients	  compared	   to	  other	   anticancer	   treatments.	   Several	   HDACi	   have	   already	   demonstrated	   preclinical	  efficacy,	  either	  alone	  or	  in	  combination	  with	  other	  anticancer	  agents	  [141].	  Moreover,	  an	   exciting	   finding	   is	   the	   observation	   that	   HDACi	   used	   at	   low	   concentrations	   are	  efficacious	  for	  treating	  a	  range	  of	  diseases	  that	  are	  not	  related	  to	  cancer.	  For	  example,	  HDACi	   exhibit	   anti-­‐inflammatory	   properties	   due	   to	   a	   reduction	   of	   cytokine	  production	   as	  well	   as	   inhibition	   of	   cytokine	   effects	   [152,153].	   Furthermore,	   HDACi	  have	  shown	  beneficial	  effects	   in	  neurodegenerative	  conditions	  and	  autoimmunity	   in	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mouse	  models	   [153,154].	   It	   is	   likely	   that	  a	  specific	  HDACi	  will	  have	  clinical	  benefits	  only	  in	  a	  specific	  tumour	  type	  and/or	  in	  a	  subset	  of	  patients.	  For	  future	  treatment	  and	  effective	   selection	   of	   the	   ‘‘right’’	   HDACi	   for	   a	   given	   therapy,	   the	   availability	   of	  predictive	  and	  prognostic	  biomarkers	  will	  be	  crucial.	  Recently,	  a	  possible	  candidate	  cancer	  biomarker	  to	  evaluate	  HDACi	  sensitivity	  in	  CTCL	  patients	  has	  been	  described	  [155,156].	  	  
Cell	  cycle	  
The	  cell	  cycle	   is	  a	  complex	  process	  that	  directs	  a	  cell	   through	  a	  specific	  sequence	  of	  events	   culminating	   in	   the	   production	   of	   two	   daughter	   cells	   with	   an	   identical	   and	  intact	  set	  of	  chromosomes.	  The	  cell	  cycle	  is	  divided	  into	  two	  stages	  (Figure	  5):	  mitosis	  (M),	  the	  real	  event	  of	  division,	  and	  interphase,	  the	  interlude	  between	  two	  M	  phases.	  The	   interphase	   includes	  G1,	   S	   and	  G2	  phases	   [157].	  Replication	  of	  DNA	  occurs	   in	   a	  specific	  part	  of	  the	  interphase	  called	  S	  phase.	  S	  phase	  is	  preceded	  by	  a	  gap	  called	  G1	  during	  which	  the	  cell	  is	  preparing	  for	  DNA	  synthesis	  and	  is	  followed	  by	  a	  gap	  called	  G2	  during	  which	  the	  cell	  prepares	   for	  mitosis.	  Cells	   in	  G1	  can,	  before	  committing	  to	  DNA	  replication,	  enter	  a	  resting	  state	  called	  G0.	  Cells	  in	  G0	  account	  for	  the	  major	  part	  of	  the	  non-­‐growing,	  non-­‐proliferating	  cells	  in	  the	  human	  body	  [158].	  To	  survive	  many	  rounds	  of	  divisions	  through	  its	  lifetime,	  a	  cell	  needs	  to	  maintain	  its	  genomic	  stability.	  The	   proper	   inheritance	   of	   an	   intact	   genome	   is	   kept	   in	   check	   by	   the	   presence	   of	  checkpoints,	  which	  monitor	   the	  proper	   execution	  of	   cell	   cycle	  phases.	   For	   instance,	  the	   DNA	   damage	   and	   spindle	   assembly	   checkpoints	   ensure	   genomic	   integrity	   by	  delaying	   cell	   cycle	   progression	   in	   the	   presence	   of	   DNA	   or	   spindle	   damage,	  respectively.	  More	  recently,	  another	  checkpoint	  has	  gained	  attention,	   the	  antephase	  checkpoint	  that	  acts	  to	  prevent	  cells	  from	  entering	  mitosis	  in	  response	  to	  a	  range	  of	  stress	  agents	  [159].	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Figure	  5.	  The	  cell	  cycle	  phases	  and	  checkpoints	  Visual	   representation	   of	   the	   cell	   cycle	   phases.	   The	  DNA	   replication	   (blue	   box),	   DNA	   damage	   (red	   box)	   and	   the	  spindle	   assembly	   checkpoints	   (gray	   box)	   as	  well	   as	   the	   antephase	   checkpoint	   (green	   box)	   are	   reported.	   (From	  
[159])	  
	   	  Mitosis	   is	   by	   far	   the	   most	   complex	   phase	   of	   the	   whole	   cell	   cycle	   and	   it	   is	   further	  divided	  in	  sub-­‐phases	  characterized	  by	  specific	  molecular	  events	  [160].	  The	   spatiotemporal	   control	   of	   all	   the	   mitotic	   events	   is	   mainly	   achieved	   through	   a	  massive	   and	   reversible	   phosphorylation	   of	   key	   regulatory	   proteins,	   which	   induces	  conformational	  changes	  and	  enhances	  the	  binding	  for	  ligands	  in	  a	  rapid	  way.	  [161].	  A	  high-­‐throughput	  mass	  spectrometry	  screen	  of	  total	  phosphorylation	  in	  mitotic	  HeLa	  cells	  identified	  phosphorylation	  on	  more	  than	  3500	  proteins	  [162].	  	  Critical	  regulators	  of	  the	  mitotic	  machinery	  are	  specific	  kinases	  and	  phosphatases,	  in	  turn	  tightly	  regulated	  in	  space	  and	  time.	  In	  mammals,	   four	  main	   families	  of	  mitotic-­‐specific	  kinases	  have	  been	   identified:	   the	  Cdks	  (Cyclin	  dependent	  kinase),	  the	  Aurora	  kinases,	  the	  Plks	  (Polo-­‐like	  kinases)	  and	  the	  Nerks	  (NIMA	  related	  kinases)	  [160].	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The	  Aurora	  kinase	  family	  Aurora	  kinases	  are	  serine/threonine	  kinases	  expressed	  and	  activated	  specifically	   in	  mitosis.	  They	  were	  first	  identified	  in	  Drosophila	  and	  yeast	  [163,164].	  The	  mammalian	  genome	   encodes	   three	   Aurora	   kinase	   proteins:	   Aurora	   A,	   B	   and	   C.	   From	   an	  evolutionary	  point	  of	  view,	  Aurora	  A	  and	  B	  originated	  from	  a	  common	  ancestor	  gene	  while	  Aurora	  C	  evolved	   from	  the	  B	   type	   [165].	  Aurora	  C	   is	  exclusively	  expressed	   in	  the	  testis,	  where	  it	  plays	  a	  role	  during	  spermatogenesis	  [166].	  Conversely,	  Aurora	  A	  and	  B	  are	  ubiquitously	  expressed	  in	  all	  tissues.	  Aurora	   kinases	   possess	   a	   well-­‐conserved	   catalytic	   domain,	   characterized	   by	   the	  presence	   of	   an	   auto-­‐activation	   loop;	   for	   the	   complete	   activation	   of	   the	   enzymes,	  specific	   threonine	   residues	   in	   this	   loop	   (T288	   for	  Aurora	  A,	  T232	   for	  Aurora	  B	  and	  T139	  for	  Aurora	  C)	  are	  required	  to	  be	  auto-­‐phosphorylated.	  Aurora	  kinases	  A	  and	  B	  also	  have	  two	  regulatory	  domains	  involved	  in	  their	  degradation	  at	  the	  end	  of	  mitosis:	  a	  D-­‐Box-­‐activating	  box	  (DAD/A-­‐Box)	  in	  the	  N-­‐terminal	  part	  and	  a	  destruction	  box	  (D-­‐box)	  in	  the	  C-­‐terminal	  part.	  Aurora	  C	  seems	  to	  possess	  only	  the	  D-­‐box	  [167]	  (Figure	  6).	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  
Figure	  6.	  The	  Aurora	  kinases	  family	  Modular	  domain	  organization	  of	  the	  human	  Aurora	  kinases	  A,	  B	  and	  C.	  The	  auto-­‐activation	  loop	  (yellow)	  as	  well	  as	  the	  activation	  (red)	  and	  disruption	  (blue)	  box	  are	  reported.	  The	  percentage	  on	   the	  right	   indicates	   the	  sequence	  identities	  among	  the	  three	  kinases.	  (From	  [168])	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Despite	  their	  common	  origin	  and	  structural	  similarity,	  Aurora	  kinases	  A	  and	  B	  have	  distinct	  roles	  in	  mitosis,	  and	  are	  quite	  separated	  in	  time	  and	  space.	  	  Aurora	  A	  is	  activated	  in	  late	  G2	  by	  binding	  with	  specific	  cofactors	  such	  as	  the	  protein	  Ajuba	   and	   TPX	   (a	   microtubule	   associated	   protein),	   which	   then	   also	   stimulates	   its	  auto-­‐phosphorylation	   in	   the	   activation	   loop	   [169,170].	   Aurora	   A	   locates	   at	  centrosomes	   in	   late	   G2	   (Figure	   7).	   The	   recruitment	   of	   Aurora	   A	   on	   centrosomes	  facilitates	  centrosome	  maturation	  and	  microtubule	  nucleation	  by	  recruiting	  and	  thus	  phosphorylating	  centrosomal	  components	  such	  as	  γ	   tubulin	  and	  centrosomin	  [170].	  	  Several	  studies	  have	  shown	  a	  role	  for	  Aurora	  A	  in	  promoting	  timely	  mitotic	  onset	  by	  controlling	   the	   centrosomal	   activation	   of	   the	   Cdk1-­‐cyclin	   B	   complex	   and	   thus	  promoting	   the	   G2/M	   transition	   [169,171].	   Aurora	   A	   also	   phosphorylates	   the	  centrosomal	   Cdc25B	   phosphatase,	   which	   is	   also	   involved	   in	   the	   activation	   of	   the	  Cdk1-­‐cyclin	  B	  complex	  [172].	  Aurora	  A	  is	  a	  crucial	  factor	  also	  for	  proper	  centrosomal	  migration:	  its	  depletion	  in	  fact	  causes	  the	  formation	  of	  monopolar	  spindles.	  Aurora	   B	   localizes	   to	   kinethocores	   from	   prophase	   to	   metaphase,	   in	   the	   mid-­‐zone	  during	  anaphase	  and	  in	  midbody	  in	  cytokinesis	  (figure	  7)	  [167,173].	  The	  activation	  of	  Aurora	  B	  requires	  the	  binding	  to	  INCENP	  (Inner	  centromere	  protein).	  Aurora	  B	  and	  INCENP,	   together	   with	   survivin,	   are	   part	   of	   the	   so-­‐called	   chromosome	   passenger	  complex	   (CPC),	  which	  plays	   different	   roles	   in	   regulating	   kinetochore	   attachment	   to	  chromosomes,	   the	   spindle	   checkpoint,	   metaphase-­‐anaphase	   transition	   and	  cytokinesis	  [174].	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Figure	  7.	  Aurora	  kinases	  A	  and	  B	  localization	  Aurora	   A	   and	   B	   localized	   differently	   in	   time	   and	   space	   during	   mitosis.	   Aurora	   A	   (upper	   panel)	   locates	   to	  centrosome/spindle	   poles	   in	   metaphase	   and	   telophase,	   whereas	   Aurora	   B	   (lower	   panel)	   is	   present	   in	   the	  centromere	   from	   prometaphase	   to	   metaphase	   and	   then	   in	   the	   spindle	   midzone	   microtubles	   in	   late	   anaphase.	  (Modified	  from	  [175])	  	  
	  	  In	  prophase,	  Aurora	  B	   is	   the	  main	  kinase	   involved	   in	  phosphorylation	  of	  serines	  10	  and	   28	   of	   histone	   3	   and	   of	   serine	   7	   of	   the	   centromeric	   histone	   variant	   CENPA	  (Centromere	   protein	   A),	   even	   though	   the	   precise	   biological	   meaning	   of	   these	  modifications	   is	   still	   unclear	   [176].	   Aurora	   B	   is	   required	   for	   proper	   chromosome	  condensation	   and	   to	   remove	   sister	   chromatid	   cohesion	   during	   mitosis.	   Moreover,	  Aurora	  B	  plays	  a	  central	  role	   in	  the	  events	  connected	  with	  kinetochore-­‐microtubule	  attachment	   and	   the	   spindle	   assembly	   checkpoint;	   for	   example,	   Aurora	   B	  phosphorylates	   MCAK	   (Mitotic	   Centromere-­‐Associated	   Kinesin)	   and	   Hec1	   (Highly	  expressed	   protein	   in	   cancer	   1)/Ndc80,	   and	   this	   results	   in	   the	   inhibition	   of	   its	  microtubule	   depolymerizing	   activity,	   a	   process	   involved	   in	   the	   control	   of	   bipolar	  orientation	  of	  metaphasic	  chromosomes	  [177].	  Finally,	  Aurora	  B	  is	  also	  required	  for	  proper	   cytokinesis;	   it	   localizes	   at	   the	   midbody	   and	   phosphorylates	   many	   proteins	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involved	   in	   cytokinesis	   such	   as	   vimentin	   [178],	   the	   kinesin	   ZEN-­‐4/MKLP1	   (mitotic	  kinesin-­‐like	  protein	  1)	  [179]	  and	  the	  GTPase	  activating	  protein	  MgcRacGAP	  [180].	  	  Both	  Aurora	  A	  and	  B	  are	  targets	  of	  the	  multisubunit	  ubiquitin	  E3	  ligase	  APC/C,	  which	  degrades	  them	  at	  the	  exit	  of	  mitosis	  ensuring	  a	  low	  level	  of	  the	  kinase	  when	  cells	  re-­‐enter	  in	  G1	  [181,182].	  Besides	  the	  APC/C	  also	  a	  cullin	  3-­‐based	  E3	  ligase	  was	  shown	  to	  ubiquitinate	  Aurora	  B,	   leading	   to	  Aurora	  B	  degradation	   from	  mitotic	   chromosomes,	  and	  ensuring	  proper	  chromosome	  decondensation	  and	  nuclear	  membrane	  assembly	  in	  telophase	  [183,184].	  	  
HDAC1	   and	   HDAC2	   Aurora-­‐dependent	   phosphorylation:	   a	  
new	  PTM	  for	  the	  two	  deacetylases	  	  




Figure	  8.	  HDAC1	  and	  HDAC2	  are	  specifically	  phosphorylated	  in	  mitosis	  
A.	  HeLa	  cells	  were	  synchronized	  in	  different	  phases	  and	  protein	  lysates	  were	  analysed	  by	  western	  blot	  with	  the	  indicated	  antibodies.	  Cell	  synchronization	  was	  evaluated	  by	  FACS	  by	  measuring	  DNA	  content	  and	  phosphorylation	  levels	  of	  serine	  10	  of	  histone	  3	  (pS10-­‐H3)	  is	  used	  as	  a	  mitotic	  marker.	  Percentages	  of	  pS10-­‐H3-­‐positive	  cells	  are	  reported.	  Vinculin	  is	  used	  as	  a	  loading	  control.	  Asterisks	  indicate	  the	  lower	  migrated	  bands.	  B.	  Mitotic	  and	  control	  asynchronous	  HeLa	  cell	  lysates	  were	  treated	  with	  calf	  intestinal	  phosphatase	  for	  1	  hour	  at	  30°C	  and	  then	  samples	  were	  analysed	  by	  western	  blot	  with	  indicated	  antibodies.	  Cdc27c	  is	  widely	  phosphorylated	  in	  mitosis	  and	  here	  is	  used	  as	  positive	  control	  for	  the	  assay.	  	  
	  
	  Moreover,	   our	   in	   silico	   analysis	   predicted	   putative	   consensus	   sites	   on	   HDAC1	   and	  HDAC2	   sequences	   for	   the	   mitotic	   Aurora	   kinases	   A	   and	   B.	   RNA	   interference	  experiments,	   with	   siRNA	   specific	   for	   the	   two	   kinases,	   (Figure	   9)	   validated	   the	  hypothesis	  that	  Aurora	  A	  and	  B	  underlie	  HDAC1	  and	  HDAC2	  mitotic	  phosphorylation.	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Figure	  9.	  Aurora	  A	  and	  B	  kinases	  selectively	  phosphorylate	  HDAC1	  and	  HDAC2	  during	  mitosis	  HeLa	   cells	   were	   subjected	   to	   two	   cycles	   of	   RNA	   interference	   with	   the	   indicated	   siRNA,	   synchronized	   at	   G1/S	  boundary	   and	   released	  with	   nocodazole.	   Cells	  were	   collected	   at	   9.5	   hours	   by	  mitotic	   shaking	   and	   analysed	   by	  western	   blot	  with	   the	   indicated	   antibodies.	   Cdc25c	   phosphorylation	   is	   used	   as	  mitotic	  marker	   and	   Vinculin	   as	  loading	  control.	  Asterisks	  indicate	  phosphorylated	  bands.	  
	  	  Aurora	   kinases	   recognize	   a	   basic	   sequence	   on	   their	   substrates	   and	   usually	  phosphorylate	   a	   serine	   residue	   within	   these	   motifs.	   Thus,	   once	   we	   identified	   on	  HDAC1	  and	  HDAC2	  putative	   consensus	   sequences	   for	  Aurora	   kinases	   (Figure	  10A),	  and	  generated	  by	  PCR	  site-­‐directed	  mutagenesis	  a	   series	  of	   constructs	   in	  which	  we	  mutated	  the	  phosphorylable	  serine	  with	  an	  unphosphorylable	  alanine,	  we	  were	  also	  able	  to	  map	  the	  Aurora	  phosphorylation	  sites	  on	  serine	  406	  of	  HDAC1	  and	  serine	  407	  of	  HDAC2	  (Figure	  10B).	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Figure	  10.	  HDAC1	  Serine	  406	  and	  HDAC2	  Serine	  407	  are	  target	  sites	  for	  Aurora	  kinases	  in	  vivo	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metaphase	   chromatin.	  Again,	   phosphorylation	   rapidly	  decreased	   as	   cells	   proceeded	  through	  anaphase,	  telophase	  and	  exit	  mitosis	  into	  a	  new	  interphase.	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  
Figure	  11.	  Phosphorylation	  of	  HDAC1	  at	  serine	  406	  occurs	  in	  prophase	  and	  is	  removed	  in	  anaphase	  HeLa	  cells	  were	  plated	  on	  poly-­‐D-­‐lysine-­‐covered	  coverslips,	  synchronized	  by	  double	  thymdine	  block,	  released	  in	  fresh	  medium	  without	  nocodazole	  and	  fixed	  with	  paraformaldehyde	  4%	  after	  9.5	  hours.	  Coverslips	  were	  stained	  using	  the	  indicated	  antibodies	  and	  DAPI	  for	  DNA	  and	  analyzed	  by	  confocal	  microscopy.	  Asterisks	  indicate	  the	  cell	  of	   interest	   in	   every	   field.	   Sub-­‐phases	   of	   mitosis	   were	   identified	   by	   the	   condensation	   status	   of	   chromatin.	   A	  reference	  scale	  bar	  of	  5μm	  is	  reported	  in	  panel	  A1.	  
	  	  	  	  	  
	  
	  38	  
Aim	  of	  the	  project	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Materials	  and	  Methods	  
	  
Cell	  lines	  and	  culture	  conditions	  HeLa	   cells	   were	   maintained	   in	   Dulbecco’s	   modified	   Eagle’s	   medium	   (Lonza)	  supplemented	  with	  10%	  fetal	  bovine	  serum	  (Lonza),	  2	  mM	  L-­‐glutamine	  (Lonza)	  and	  antibiotics	  (250	  μg/ml	  penicillin	  and	  25	  μg/ml	  streptomycin).	  Cells	  were	  cultured	  in	  a	  humidified	  37°C	  incubator	  with	  5%	  CO2.	  
	  
Cell	  synchronization	  To	   synchronize	   cells	   in	   mitosis,	   330	   nM	   nocodazole	   was	   added	   for	   16	   hours	   and	  mitotic,	   rounded-­‐up	   cells	   were	   harvested	   by	   shaking	   them	   off	   culture	   dishes.	   Cells	  were	   synchronized	   at	   the	   G1/S	   boundary	   by	   double	   thymidine	   block:	   cells	   were	  treated	   with	   2	   mM	   thymidine	   overnight,	   followed	   by	   wash	   and	   release	   in	   fresh	  medium.	   The	   protocol	   was	   performed	   for	   two	   consecutive	   days.	   The	   G2-­‐enriched	  population	  is	  the	  one	  that	  remains	  attached	  to	  the	  plate	  upon	  nocodazole	  treatment	  and	  mitotic	  shaking.	  G1	  pure	  population	  was	  obtained	  from	  mitotic	  cells	  released	  for	  2	  hours	  from	  nocodazole	  block	  in	  order	  to	  re-­‐enter	  synchronously	  in	  a	  new	  G1.	  If	  modifications	  were	  introduced,	  they	  are	  indicated	  in	  the	  corresponding	  experiment.	  	  
Production	  and	  purification	  of	  GST	  tag	  proteins	  GST	   tag	   proteins	   were	   produced	   in	   bacteria	   and	   purified	   with	   Glutathion®	   beads	  (Sigma).	   Proteins	   were	   eluted	   using	   reduced	   glutathione	   and	   the	   GST	   tag	   was	  removed	   through	   proteolytic	   cleavage	   with	   PreScission	   protease	   (produced	   as	  recombinant	  protein	  at	  IFOM-­‐IEO-­‐Campus).	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Quantification	  of	  purified	  recombinant	  protein	  was	  performed	  by	  SDS-­‐PAGE	  and	  gel	  staining	  with	  Coomassie	  Brilliant	  Blue,	  by	   comparison	  with	  known	  amounts	  of	  BSA	  protein.	  	  
In	  vitro	  Aurora	  kinase	  assay	  Aurora	  kinase	  assays	  were	  performed	  as	  previously	  described	  [185].	  Briefly,	  1	  µg	  of	  purified	  substrate	  (HDAC1,	  HDAC2,	  HDAC3	  or	  histone	  H3)	  were	  incubated	  with	  50	  ng	  of	  recombinant-­‐purified	  Aurora	  A/TBX2	  or	  Aurora	  B/INCEP	  kinase	  in	  the	  presence	  of	  5	   µCi	   of	   γ-­‐32pATP	   at	   30°C	   for	   1	   hour	   and	   analyzed	   by	   SDS-­‐PAGE	   followed	   by	  autoradiography.	  	  
In	  vitro	  histone	  deacetylase	  assay	  FLAG-­‐tagged	   HDACs	   were	   transfected	   in	   cells	   and	   immune-­‐precipitated.	   Purified	  complexes	  were	   then	   incubated	  with	  100	  µCi	  of	   chicken	  purified	  H3-­‐acetyl	  histones	  (kindly	  provided	  by	  Christian	  Seiser)	  in	  E1A	  buffer	  [(50	  mM	  Hepes	  pH	  7.5,	  250	  mM	  NaCl,	  0.1%	  NP-­‐40)	  PMSF,	  leupeptin,	  aprotin,	  sodium	  orthovanadate,	  sodium	  fluoride	  and	  NEM	  were	   freshly	  added	   immediately	  before	  use]	   for	  1	  hour	  at	  30°C.	  H3-­‐acetyl	  groups	   released	   were	   extracted	   with	   a	   two-­‐phase	   acqueous-­‐ethyl	   acetate	   solution	  and	  radioactivity	  measured	  as	  counts	  per	  minute	  (c.p.m.)	  in	  a	  ß-­‐counter	  scintillation	  machine.	  
	  
Plasmids	  and	  vectors	  For	   expression	   in	   human	   cells	   the	   pBJ5-­‐HDAC1-­‐Flag	   and	   pCDNA3.1c-­‐Flag-­‐HDAC2	  plasmids	  were	   used.	   For	   expression	   of	   recombinant	   proteins	   in	   bacteria	   the	   pGEX-­‐6P1-­‐GST-­‐HDAC1,	   pGEX-­‐6P1-­‐GST-­‐HDAC2	   and	   pGEX-­‐6P1-­‐GST-­‐HDAC3	   plasmids	   were	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used.	   Plasmids	   for	   production	   of	   Aurora	   kinases	   have	   been	   previously	   described	  
[185,186].	   Point	  mutant	   HDAC1	   and	   HDAC2	   proteins	   were	   generated	   by	   PCR	   site	  directed	  mutagenesis	  of	  pBJ5-­‐HDAC1	  and	  pCDNA3.1c-­‐HDAC2	  wild	  type	  using	  primers	  carrying	   the	   desired	   mutations.	   For	   retroviral	   infection	   in	   HeLa	   cells	   the	   pBABE-­‐PURO	  plasmid	  (empty	  or	  encoding	  HDAC1)	  was	  used.	  For	  mRNA	  transcription	  and	  injection	  in	  zebrafish	  embryos,	  the	  human	  HDAC1	  wild	  type,	   S406A	   and	   S406E	   constructs	   were	   subcloned	   into	   pCS2+	   expression	   vector	  (Addgene)	  using	  BamHI/XhoI	  restriction	  enzymes.	  	  
Site-­‐directed	  PCR	  mutagenesis	  Plasmids	   encoding	   for	   wild	   type	   HDAC1	   protein	   was	   used	   as	   template	   and	   was	  amplified	  through	  a	  PCR	  reaction	  with	  couples	  of	  primers	  (below	  reported)	  carrying	  the	   desired	   mutations.	   PCR	   products	   were	   then	   purified	   with	   the	   QIAquick®	   PCR	  Purification	   Kit	   (QIAGEN)	   and	   subjected	   to	   digestion	   with	   20	   Units	   of	   DpnI	   (New	  England	  Biolabs)	   for	  1	  hour	  at	  37°C	   to	  digest	  bacteria-­‐derived	  methylated	   template	  DNA.	  PCR	  products	  were	  then	  transformed	  by	  heat	  shock	  in	  DH5α	  E.coli	  strain;	  DNA	  from	  single	  colonies	  was	  extracted	  with	  the	  QIAGEN	  Plasmid	  Mini	  Kit	  and	  sequenced	  with	  a	  3730XL	  DNA	  Analyzer.	  	  
Cell	  transfection	  24	   hours	   before	   transfection	   cells	   were	   plated	   in	   a	   number	   such	   as	   to	   have	   50%	  confluence	   the	   day	   after.	   Transfections	   were	   performed	   according	   the	   calcium	  phosphate	   protocol.	   DNA	   containing	   solution	   was	   then	   distributed	   on	   cells	   and	  incubated	   for	   approximately	   8	   hours	   at	   37°C.	   Cells	   was	   harvest	   after	   72	   hours	   for	  further	  experiments.	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Infection	  with	  retroviral	  vectors	  	  Packaging	   Phoenix	   Ampho	   cells	   were	   transfected	   with	   retroviral	   constructs	   using	  calcium	   phosphate	   protocol	   as	   described	   above	   to	   allow	   the	   production	   of	   viral	  particles.	  24	  hours	  prior	  to	  infection,	  target	  cells	  were	  plated	  in	  10	  cm	  dishes	  in	  order	  to	   reach	   a	   confluence	   of	   50%	   the	   day	   of	   infection.	   The	   medium	   containing	   viral	  particles	  was	  collected,	  filtered	  with	  a	  0.22	  µM	  filter	  and	  added	  to	  the	  target	  cells	  for	  6	  hours	   in	   the	   presence	   of	   5	  µg/ml	  polybrene.	   The	  day	   after,	   cells	  were	   subjected	   to	  another	  cycle	  of	  infection.	  24	  hours	  after	  the	  second	  infection	  puromycin	  was	  added	  at	  a	  concentration	  of	  1	  µg/ml	  and	  cells	  were	  kept	   in	  selection	   for	  at	   least	  4	  days	   to	  select	  for	  a	  stable	  population	  before	  further	  experiments	  were	  performed.	  	  
Growth	  curves	  	  HeLa	  cells	  were	  counted	  using	  the	  trypan	  blue	  dye	  and	  1500	  cells/well	  were	  plated	  in	  a	  96-­‐well.	  Every	  condition	  was	  plated	  in	  triplicate	  for	  all	  the	  considered	  time	  points.	  The	  day	  of	  plating	  is	  referred	  to	  as	  T0.	  Cell	  viability	  was	  measured	  every	  24	  hours	  for	  4	   days	   by	   CellTiter-­‐Glo®	   Luminescent	   Cell	   Viability	   Assay	   according	   to	  manufacturer’s	   instruction.	   The	   number	   of	   viable	   cells	   in	   culture	   is	   determined	   by	  quantitation	  of	  the	  ATP	  present,	  as	  an	  indicator	  of	  metabolically	  active	  cells.	  
	  
Colony	  forming	  assay	  	  HeLa	  cells	  were	  counted	  using	  the	  trypan	  blue	  dye	  and	  3000	  viable	  cells	  were	  plated	  into	  a	  10	  cm	  dish.	  Eight	  days	  after	  plating,	  cells	  were	   fixed	  and	  stained	  with	  crystal	  violet	   solution	   (1%	   crystal	   violet,	   35%	   ethanol	   in	   PBS)	   and	   colonies	  were	   counted	  using	  Image	  J	  software.	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Western	  blot	  analysis	  	  For	  Western	  blot	  analysis	  cells	  were	  lysed	  in	  denaturing	  SDS	  lysis	  buffer	  [one	  volume	  of	  Buffer	  I	  (5%	  SDS,	  150	  mM	  Tris-­‐HCl	  pH	  6.8,	  30%	  glycerol)	  +	  three	  volumes	  of	  Buffer	  II	  (25	  mM	  Tris-­‐HCl	  pH	  8.3,	  50	  mM	  NaCl,	  0.5%	  NP-­‐40,	  0.5%	  deoxycholate,	  0.1%	  SDS)	  +	  aprotinin	   and	   leupeptin,	   sodium	   fluoride,	   sodium	   pyrophosphate	   and	   sodium	  orthovanadate].	  	  For	  HDAC1	   detection	   in	   zebrafish,	   3	   days	   embryos	  were	   lysed	   in	   urea	   buffer	   (8	  M	  Urea,	  0.1	  M	  NaH2PO4,	  0.01	  M	  Tris,	  pH	  8).	  	  The	   following	   antibodies	   were	   used	   for	   western	   blot:	   HDAC1	   mouse,	   clone	   10E2	  produced	   in	   house	   by	   Christian	   Seiser,	   HDAC1	   (Abcam),	   HDAC2	   rabbit	   (Abcam),	  HDAC3	  rabbit	  (Abcam),	  vinculin	  mouse	  (Santa	  Cruz),	  phospho-­‐serine421/423	  HDAC1	  (Millipore),	   histone	   H3	   (Abcam),	   RbAp48	   (Upstate),	   acetylated	   H3K9	   (Abcam),	  phospho-­‐serine10	  histone	  H3	  rabbit	  (Upstate),	  Cdc25c	  rabbit	  (Santa	  Cruz),	  cyclin	  B1	  mouse	  (Santa	  Cruz),	  Flag	  mouse	  (Sigma),	  zebrafish	  HDAC1	  rabbit	  (Abcam).	  	  	  
Immunoprecipitations	  Cells	  were	  lysed	  in	  non-­‐denaturing	  E1A	  buffer	  [(50	  mM	  Hepes	  pH	  7.5,	  250	  mM	  NaCl,	  0.1%	  NP-­‐40)	   PMSF,	   leupeptin,	   aprotin,	   sodium	  orthovanadate,	   sodium	   fluoride	   and	  NEM	   were	   freshly	   added	   immediately	   before	   use].	   Immunoprecipitation	   (IP)	   was	  performed	  incubating	  protein	  extracts	  with	  the	  antibody	  of	  interest	  at	  ratio	  of	  3-­‐4	  mg	  Ab/mg	  of	  crude	  extract	  for	  16	  hours	  at	  4	  °C	  on	  rotation.	  Then	  protein-­‐A/sepharose-­‐beads	  (slurry	  50%)	  were	  added	  to	  the	  samples	  for	  2	  hours	  at	  4	  °C.	  Beads	  were	  then	  extensively	   washed	   with	   cold	   E1A	   buffer,	   loaded	   on	   SDS-­‐PAGE	   and	   analyzed	   by	  western	  blot	  with	   the	   indicated	   antibodies.	   Total	   extracts	   (input)	  were	   loaded	   as	   a	  control.	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Zebrafish	  strains	  and	  maintenance	  Zebrafish	   strains	   were	   maintained	   and	   bred	   according	   to	   standard	   procedures.	  Embryos	  from	  AB	  wild	  type	  strain	  were	  maintained	  in	  E3	  water	  (5	  mM	  NaCl,	  0.17	  mM	  KCl,	  0.33	  mM	  CaCl2,	  0.33	  mM	  MgSO4)	  at	  28.5ºC.	  
	  
Ethics	  statement	  Fish	  were	  maintained/raised	  according	  to	  EU	  regulations	  on	  laboratory	  animals.	  
	  
mRNAs	  and	  morpholino	  injections	  in	  zebrafish	  embryos	  mRNAs	   were	   synthesized	   from	   NotI	   digested	   pCS2+-­‐hHDAC1	   wt,	   S406A,	   S406E	  plasmids	   using	  mMessage	  mMachine	   kit	   (Ambion)	   and	  purified	  with	  Microcon	  YM-­‐100	   (Millipore)	   filter	   devices.	   RNA	   quality	   was	   assayed	   by	   means	   of	   gel	  electrophoresis.	  mRNAs	  was	   then	  diluted	   in	   1X	  Danieau	   solution	   (58	  mM	  NaCl,	   0.7	  mM	   KCl,	   0.4	   mM	   MgSO4,	   0.6	   mM	   Ca(NO3)2,	   5	   mM	   HEPES,	   pH	   7.6)	   at	   final	  concentration	  of	  120	  ng/λ	  and	  pressure	  injected	  into	  1-­‐2	  cell	  stage	  embryos.	  Morpholinos	  were	  purchased	  by	  Gene	  Tools,	  LLC.	  The	  morpholino	  against	  hdac1	  (5’-­‐TTGTTCCTTGAGAACTCAGCGCCAT-­‐3’)	  was	  targeted	  to	  the	  translational	  initiation	  site,	  as	   [110].	   The	   scramble	   morpholino	   sequences	   was:	   5’-­‐CCTCTTACCTCAGTTACAATTTATA-­‐3’.	   Morpholinos	   (0.15	   mM)	   were	   diluted	   and	  injected	  as	  described	  above.	  	  	  
Zebrafish	  embryo	  cell	  dissociation	  	  Embryos	  were	  anesthetized	  with	  tricaine	  and	  decapitated.	  After	  transient	  storage	  in	  PBS	   on	   ice,	   heads	   were	   incubated	   in	   trypsin-­‐EDTA	   (Lonza)	   for	   30	   min	   at	   37°C.	  Afterward,	  heads	  were	   transferred	   to	   fresh	  PBS	  and	  mechanically	  disgregated.	  This	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treatment	  led	  to	  a	  single-­‐cell	  suspension.	  Cells	  were	  harvested	  by	  centrifugation	  for	  3	  min	  at	  3000	  ×	  g	  at	  4°C,	  resuspended	  in	  PBS	  and	  used	  for	  further	  experiments.	  	  	  
FACS	  analysis	  For	  FACS	  analysis,	  cell	  suspension	  obtained	  as	  above	  mentioned	  was	  fixed	  in	  ice-­‐cold	  70%	   ethanol	   and	   incubated	   over	   night	   on	   ice.	   DNA	   was	   stained	   with	   a	   solution	  containing	  2.5	  µg/ml	  propidium	  iodide	  (PI)	  (Sigma)	  and	  250	  µg/ml	  RNase	  A.	  Samples	  were	  acquired	  on	  a	  FACSCanto	   flow	  cytometer	  and	  analysis	  was	  performed	  using	  a	  DIVA	  6.1.1	  machine.	  	  
Chromatin	   immunoprecipitation	   (ChIP)	   and	   quantitative	   real-­‐time	   PCR	  
(qPCR)	  For	   each	  batch	  of	   chromatin,	   70	  wild-­‐type	   (AB),	   hHDAC1	  mutants,	   scramble	  MO	  or	  hdac1	  morphant	  embryos	  were	  enzymatically	  dechorionated	  at	  72	  hpf,	  anesthetized	  with	  tricaine	  and	  decapitated.	  Embryos	  heads	  were	  dissociated	  as	  above	  mentioned	  and	   fixed	   immediately	   in	   1.5%	   formaldehyde	   for	   10	  minutes.	   Glycine	   (2.5	   M)	   was	  added	  to	  quench	  the	   formaldehyde	  and	  cell	  suspension	  was	  washed	   in	   ice	  cold	  PBS	  and	  then	  lysed	  in	  RIPA	  buffer	  [(10	  mM	  Tris-­‐HCl	  pH	  8.0,	  1	  mM	  EDTA	  pH	  8.0,	  140	  mM	  NaCl,	  1%	  Triton	  X-­‐100,	  0.1%	  SDS,	  0.1%	  Na-­‐Deoxycholate)	  PMSF,	   leupeptin,	  aprotin,	  sodium	   orthovanadate,	   sodium	   fluoride	   were	   added	   before	   use].	   Chromatin	   was	  sheared	  by	   sonication	   to	   give	  DNA	   fragments	   of	   approximately	   300-­‐700	  bp	   in	   size.	  Sonicated	  samples	  were	  centrifuged	  at	  12000	  ×	  g	  at	  4°C	  for	  15	  minutes,	  and	  insoluble	  material	   was	   discarded.	   The	   supernatant	   was	   incubated	   with	   acetylated	   H3K27	  antibody	   (Abcam)	  or	   control	   IgG	   antibody	   (Abcam).	  Dynabeads	  Protein	  G	  magnetic	  beads	   (Invitrogen)	   were	   added	   to	   each	   sample	   and	   the	   samples	   rotated	   at	   4°C	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overnight.	   Beads	  were	  washed	   six	   times	  with	  RIPA	  washing	   buffer	   (50	  mM	  Hepes-­‐KOH	  pH	  7.5,	  500	  mM	  LiCl,	  1	  mM	  EDTA,	  1%	  NP-­‐40,	  0.7%	  Na-­‐Deoxycholate)	  at	  4°C	  and	  bound	  complexes	  were	  eluted	   from	   the	  beads	   in	  Elution	  Buffer	   (1x	  TE,	  2%	  SDS)	  at	  65°C	  for	  20	  minutes	  with	  vortexing.	  Cross-­‐links	  were	  reversed	  overnight	  at	  65°C	  and	  DNA	   fragments	   were	   purified	   with	   Qiaquick	   purification	   kit	   (Qiagen).	   Quantitative	  real-­‐time	   PCR	   (QPCR)	   of	   immuno-­‐precipitated	   DNA	   was	   used	   to	   validate	   ChIP	  experiment.	   QPCR	   analyses	   were	   performed	   in	   triplicate	   and	   DNA	   abundance	   was	  normalised	  against	  Input	  values.	  	  
Confocal	  immunofluorescence	  microscopy	  For	   immunostaining,	   24	   hpf	   embryos	   were	   fixed	   in	   4%	   para-­‐formaldehyde	   (PFA)	  overnight	  and	  permeabilized	  with	  acetone	  at	  -­‐20°C	  for	  7	  minutes.	  Embryos	  were	  then	  blocked	   in	  PBS	   containing	  0.5%	  Triton-­‐X,	  1%	  DMSO,	  1%	  BSA	  and	  2%	  sheep	   serum	  (PBST)	  for	  2	  hours	  at	  4°C	  and	  incubated	  with	  primary	  antibody	  overnight.	  The	  next	  day,	   embryos	   were	   rinsed	   in	   PBST	   and	   incubated	   with	   secondary	   antibody	   before	  mounting	  for	  confocal	  microscopy.	  The	   following	  primary	  antibodies	  were	  used:	  pS406-­‐HDAC1	  (clone	  BT-­‐15	  produced	  at	  IFOM-­‐IEO	  Campus),	  pS10-­‐histone	  H3	  (Upstate),	  Flag	  (Abcam).	  The	   following	   secondary	   antibodies	   were	   used:	   Alexa-­‐488	   conjugated	   mouse	   IgG,	  Alexa-­‐433	  conjugated	  rabbit	  IgG.	  	  	  
Immunohistochemistry	  (IHC)	  For	   histological	   sections	   72	   hpf	   embryos	   were	   fixed	   in	   4%	   PFA	   overnight	   and	  permeabilized	  in	  sucrose	  gradient.	  Then	  embryos	  were	  embedded	  in	  2%	  low	  agarose,	  processed	  and	   included	   in	  paraffin	  before	  sectioned	  with	  microtome.	  Sections	  were	  dehydrated	   and	   treated	   with	   Na-­‐citrate	   to	   unmask	   the	   antigen	   from	   the	   paraffin.	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Later	   they	  were	  blocked	   for	  1	  hour	  with	  blocking	   solution	   (PBS,	   1%	  BSA,	   2%	  FBS)	  and	  incubated	  with	  primary	  antibody	  overnight.	  The	  day	  after,	  section	  were	  washed	  in	  PBS	  and	  incubated	  with	  secondary	  antibody.	  Once	  they	  were	  re-­‐hydrated,	  antibody	  signal	  was	  revealed	  with	  DAB	  and	  haematoxylin	  staining	  was	  performed.	  	  For	   immunohistochemistry,	   acetylated-­‐histone	   antibody	   (clone	   T25,	   produced	   at	  IFOM-­‐IEO	  Campus)	  was	  used.	  	  	  
Primer	  sequences	  
Mutagenesis	  primers	  for	  HDAC1	  
	  
ChIP	  validation	  primers	  
	  
	  
Statistical	  analysis	  Results	   are	   reported	   as	   means	   +/-­‐	   standard	   errors.	   Statistical	   signiﬁcance	   was	  calculated	   using	   Graphpad	   PRISM.	   Different	   algorithms	   used	   are	   specified	   for	   each	  experiment.	  Values	  of	  P	  <0.05	  were	  considered	  statistically	  signiﬁcant.	  	  
	  
HDAC1&KRISI&S406A CCCTGACAAGCGCATCGCGATCTGCTCCTCTGACGTCAGAGGAGCAGATCGCGATGCGCTTGTCAGGGHDAC1&KRISI&S406E CCCTGACAAGCGCATCGAGATCTGCTCCTCTGACGTCAGAGGAGCAGATCTCGATGCGCTTGTCAGGGHDAC1&S421/423A GTGAGGAAGAGTTCGCCGATGCGGAAGAGGAGGGAGAGGCCTCTCCCTCCTCTTCCGCATCGGCGAACTCTTCCTCAC




Aurora	  kinases	  A	  and	  B	  directly	  phosphorylate	  HDAC1	  in	  vitro	  Since	   our	   previous	   findings	   indicated	   a	   specific	   role	   for	   Aurora	   kinases	   in	   HDAC1	  mitotic	   phosphorylation	   (see	   Introduction),	   we	   asked	   whether	   Aurora	   A	   and	   B	  directly	  modified	  HDAC1.	  	  Thus,	  we	  performed	  an	  in	  vitro	  kinase	  assay,	  in	  collaboration	  with	  Stefano	  Santaguida.	  Recombinant	   Aurora	   A/TPX2	   or	   Aurora	   B/INCENP	   were	   incubated	   with	   1	   µg	   of	  bacterially-­‐produced	  HDAC1,	  HDAC3	  or	  histone	  3	  as	  substrates	  in	  the	  presence	  of	  [γ-­‐	  
32P]ATP	  as	  donor	  of	  phosphate	  groups	   for	  1	  hour	  at	  30°C.	  Histone	  3	  was	  used	  as	  a	  positive	  control	  for	  Aurora	  kinases	  activity;	  HDAC3	  as	  negative	  control,	  since	  it	  is	  not	  phosphorylated	   in	   mitosis	   and	   does	   not	   possess	   any	   putative	   consensus	   site	   for	  Aurora-­‐mediated	   phosphorylation.	   The	   reaction	  was	   then	   resolved	   on	   a	   SDS-­‐PAGE	  and	  the	  gel	  exposed	  for	  autoradiography;	  the	  Coomassie	  staining	  of	  the	  gel	  was	  used	  as	  loading	  control	  (Figure	  12).	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Figure	  12.	  Aurora	  kinases	  A	  and	  B	  directly	  phosphorylate	  HDAC1	  in	  vitro	  Recombinant	   Aurora	  A/TPX2	   and	  Aurora	   B/INCENP	  were	   incubated	  with	   1	   µg	   of	  HDAC1,	  HDAC3	   or	   histone	   3	  (H3)	   as	   substrates	   with	   5	   µCi	   ATP	   (γ32P)	   for	   1	   hour	   at	   30°C.	   Samples	   were	   loaded	   on	   a	   14%	   PAA	   gel	   and	  incubated	  for	  autoradiography.	  H3	  is	  used	  as	  a	  positive	  control	  for	  Aurora	  kinase	  activity.	  Coomassie-­‐stained	  gels	  are	   reported	  as	   loading	  controls.	  Asterisks	  mark	   the	  bands	   corresponding	   to	   recombinant	  proteins.	  A	   ladder	  of	  molecular	  weight	  is	  reported,	  where	  KDa	  are	  kilo	  Daltons.	  
	  	  As	  clearly	  displayed	  in	  Figure	  12,	  both	  Aurora	  A	  and	  Aurora	  B	  phosphorylate	  HDAC1,	  while	  HDAC3,	  as	  expected,	  was	  not	  modified	  by	  the	  two	  kinases.	  	  This	  result	  shows	  that	  HDAC1	  is	  direct	  substrate	  for	  Aurora	  kinases	  A	  and	  B.	  	  
	  	  














Aurora	   kinases	   and	   Casein	   kinase	   II	   (CKII)	   phosphorylate	   HDAC1	  
independently	  	  Given	   the	   well-­‐established	   role	   of	   CKII	   in	   phosphorylating	   HDAC1	   [38,62,63],	   we	  asked	  whether	  crosstalk	  between	  the	  basal,	  constitutive	  CKII-­‐	  and	  the	  mitotic-­‐specific	  Aurora	   phosphorylation	   of	   HDAC1	   existed,	   thus	   suggesting	   the	   presence	   of	   a	  hierarchy	  in	  the	  phosphorylation	  code	  of	  the	  protein.	  To	   investigate	   this	  hypothesis,	  HeLa	  cells	  expressing	   flag	   tagged	  HDAC1	  wt,	  HDAC1	  S406A	  Aurora	  phospho-­‐null	  or	  HDAC1	  S406E	  Aurora	  phospho-­‐mimetic	  mutants	  were	  synchronized	   and	   collected	   at	   indicated	   time	   points	   (Figure	   13A-­‐B).	   Figure	   13A	  represents	   the	   trend	   of	   the	   two	   phosphorylations	   during	   cell	   cycle:	   HDAC1	   was	  constitutively	  phosphorylated	  by	  CKII	  at	  serine	  421/423,	  whereas	  Aurora-­‐dependent	  phosphorylation	  occurred	  only	  in	  mitosis	  at	  serine	  406.	  	  HeLa	  cells	  stably	  expressing	  flag-­‐tagged	  HDAC1,	  HDAC1	  S406A	  or	  HDAC1	  S406E	  were	  synchronized	  at	  G1/S	  via	  a	  double	  thymidine	  block	  and	  were	  then	  released	  into	  the	  cell	   cycle	   in	   fresh	   medium	   containing	   300nM	   nocodazole	   (Figure	   13B,	   left	   panel).	  Alternatively,	   the	   cells	   were	   synchronized	   in	   M	   phase	   by	   treatment	   with	   300nM	  nocodazole	   for	  16	  hours,	  purified	  by	  mitotic	   shaking,	  washed	  and	   released	   in	   fresh	  medium	   (Figure	   13B,	   right	   panel).	   Samples	   were	   collected	   at	   the	   indicated	   time	  points	   after	   release	   and	   then	   lysed	   in	   SDS	   denaturing	   buffer.	   Flag-­‐tagged	   HDAC1	  proteins	   were	   immunoprecipitated	   and	   tested	   with	   the	   antibody	   specific	   for	   CKII	  phosphorylation	   (pS421/423-­‐HDAC1).	   As	   shown	   in	   Figure	   13B,	   no	   substantial	  differences	  in	  the	  CKII	  phosphorylation	  levels	  were	  reported	  upon	  expression	  of	  the	  two	  different	  HDAC1	  Aurora	  phospho	  mutants	  neither	  during	  entry	  (right	  panel)	  nor	  exit	  (left	  panel)	  from	  mitosis.	  Finally,	  we	  wanted	  to	  check	  the	  opposite	  relationship:	  whether	   the	   absence	   of	   the	   basal	   CKII-­‐phosphorylation	   could	   affect	   Aurora-­‐phosphorylation	  of	  HDAC1.	  Flag-­‐tagged	  HDAC1	  wt,	  S406A	  Aurora	  phospho-­‐null	  and	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CKII	  phospho-­‐null	   (HDAC1	  S421/423A)	  proteins	  were	   transfected	   in	  HeLa	   cells.	   24	  hours	  after	  transfection,	  cells	  were	  synchronized	  in	  M	  phase	  and	  protein	  lysates	  were	  immunoprecipitated	  with	  anti	   flag	  sepharose	  beads	  and	  blotted	  with	  pS406-­‐HDAC1	  antibody.	   As	   reported	   in	   Figure	   14C,	   both	   HDAC1	  wt	   and	   HDAC1	   2S	  mutant	   were	  equally	  phosphorylated	  on	  serine	  406.	  	  All	   the	  above	  results	  suggest	   that	  CKII	  phosphorylation	  of	  HDAC1	   is	  not	  affected	  by	  the	   status	   of	   Aurora-­‐phosphorylation	   sites	   and	   that	   the	   absence	   of	   basal	   CKII	  phosphorylation	   of	   HDAC1	   does	   not	   perturb	   Aurora-­‐driven	   phosphorylation	   of	   the	  protein.	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Figure	  13.	  Aurora	  kinases	  and	  the	  CKII	  kinase	  do	  not	  crosstalk	  in	  phosphorylating	  HDAC1	  
A.	  HeLa	  cells	  were	  synchronized	  at	  the	  G1/S	  boundary	  and	  released	  as	  described	  in	  Materials	  and	  Methods	  (lanes	  1-­‐10).	   Cells	  were	   synchronized	   in	  mitosis,	   washed	   and	   released	   in	   fresh	  medium	   (lanes	   11-­‐14).	   Samples	  were	  collected	   every	   hour	   and	   analyzed	   by	  western	   blot	  with	   the	   indicated	   antibodies.	   GAPDH	  was	   used	   as	   loading	  control.	  B.	  HeLa	  cells	  stably	  expressing	  flag-­‐tagged	  HDAC1	  wild	  type,	  S406A	  or	  S406E	  mutants	  were	  synchronized	  at	  the	  G1/S	  boundary	  (left	  panel)	  or	  in	  M	  phase	  (right	  panel)	  as	  described	  in	  Materials	  and	  Methods.	  Samples	  were	  collected	   at	   the	   indicated	   time	   points	   after	   release.	   Cells	   were	   lysed	   in	   SDS	   denaturing	   buffer,	   and	   IP	   were	  performed	  against	  the	  flag	  tag.	  Samples	  were	  then	  analyzed	  by	  western	  blot	  with	  the	  indicated	  antibodies.	  pS10-­‐H3	  was	  used	  as	  marker	  of	  mitosis	  and	  total	  histone	  3	  as	  loading	  control.	  C.	  Flag	  tagged	  HDAC1	  wt,	  HDAC1	  S406A	  or	  HDAC1	  2S	  mutants	  were	  transiently	  expressed	  in	  HeLa	  cells.	  Cells	  were	  or	  not	  synchronized	  in	  M	  phase.	  Mitotic	  cells	   were	   then	   purified	   and	   lysed	   in	   SDS	   denaturing	   buffer.	   Immunoprecipitation	   against	   the	   flag	   tag	   were	  performed	   and	   samples	   were	   analyzed	   by	   western	   blot	   with	   the	   indicated	   antibodies.	   pS10-­‐H3	   was	   used	   as	  marker	  of	  mitosis	  and	  vinculin	  as	  loading	  control.	  
	  	  
Aurora	   kinase-­‐mediated	   phosphorylation	   of	   HDAC1	   reduces	   its	  
deacetylase	  activity	  in	  vitro	  but	  does	  not	  affect	  its	  interaction	  with	  HDAC2	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HeLa	   cells	   were	   transfected	   with	   flag-­‐tagged	   HDAC1	   wild	   type	   or	   the	   two	   Aurora	  phospho	  mutants:	  phospho-­‐null	  S406A	  and	  phospho-­‐mimetic	  S406E.	  	  24	  hours	   after	   transfection,	  330	  nM	  of	  nocodazole	  was	  added	   for	  16	  hours,	  mitotic	  cells	  were	  collected	  by	  shake	  off	  and	  immunoprecipitation	  was	  performed	  using	  the	  flag	   antibody.	   Three	   quarters	   of	   the	   immunoprecipitated	   HDAC1	   complexes	   were	  incubated	   with	   3CH3-­‐acetylated	   histones	   as	   substrates	   for	   1	   hour	   at	   30°C	   and	   the	  deacetylase	   activity	   was	   evaluated	   as	   radioactivity	   released	   using	   a	   scintillation	  counter.	   One	   fourth	   of	   the	   immunoprecipitation	   was	   analyzed	   by	   western	   blot	   to	  assess	  interaction	  with	  known	  binding	  partners	  and	  for	  normalization	  of	  the	  histone	  assay.	  The	  HDAC1	  2S	  mutant	  was	  included	  as	  a	  negative	  control	  for	  both	  deacetylase	  and	  binding	  activity.	  	  The	  results	  showed	  that,	  although	  the	  activity	  of	  the	  phospho-­‐mimetic	  form	  of	  HDAC1	  S406E	  was	  not	  completely	  abolished	  as	  for	  the	  HDAC1	  2S	  mutant,	  it	  was	  reduced	  by	  at	   least	   40%	   compared	   to	   the	   wild	   type,	   whereas	   the	   phospho-­‐null	   HDAC1	   S406A	  mutant	  showed	  no	  significant	  changes	  in	  its	  deacetylating	  ability	  (Figure	  14A).	  	  Moreover,	   unlike	   the	   CKII-­‐dependent	   phosphorylation,	   the	   Aurora-­‐dependent	  phosphorylation	   of	   HDAC1	   did	   not	   affect	   HDAC1/HDAC2/RbAp48	   catalytic	   core	  complex	  formation	  as	  shown	  in	  the	  western	  blot	  (Figure	  14B).	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Figure	  14.	  Aurora-­‐dependent	  phosphorylation	  of	  HDAC1	   is	  not	   involved	   in	   the	  binding	  with	  HDAC2	  and	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The	   histone	   assays	   and	   immunoprecipitations	   performed	   indicate	   that	   neither	   the	  abrogation	  nor	  the	  constitutive	  mimic	  of	  HDAC1	  Aurora-­‐dependent	  phosphorylation	  influence	   the	   ability	   of	   the	   enzyme	   to	   bind	   its	   partners	   RbAp48	   and	   HDAC2.	   By	  contrast,	   only	   the	   phospho-­‐mimetic	   form	   S406E,	   at	   least	   in	   the	   in	   vitro	   conditions	  used,	   has	   an	   impact	   on	   HDAC1	   catalytic	   activity	   significantly	   decreasing	   its	  deacetylase	  properties.	  	  
Aurora-­‐mediated	   HDAC1	   phosphorylation	   slightly	   affects	   H3K9	  
deacetylase	  activity	  in	  mammalian	  cells	  Since	   the	   histone	   assay	   reported	   above	   was	   performed	   in	   vitro,	   using	   histones	  purified	   from	   chicken	   cell	   nuclear	   extracts,	   we	   wanted	   to	   confirm	   the	   differences	  observed	   in	   the	   enzymatic	   abilities	   of	  HDAC1	  wt	   compared	   to	   the	  Aurora	   phospho	  mutant	  in	  a	  more	  physiological	  setting.	  HeLa	  cells,	  expressing	  flag-­‐tagged	  HDAC1	  wt	  or	  S406A	  and	  S406E	  HDAC1	  mutants,	  were	  synchronized	  in	  M	  phase	  and	  mitotic	  cells	  were	  collected	  by	  shake-­‐off	  after	  16	  hours	  of	  nocodazole	  treatment	  and	  analyzed	  by	  SDS–PAGE	  and	  western	  blot	  (Figure	  15A).	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Figure	   15.	   HDAC1	   Aurora-­‐dependent	   phosphorylation	   slightly	   affects	   H3K9	   acetylation	   in	   mammalian	  
cells	  HeLa	  cells	  were	  stably	  infected	  with	  flag-­‐tagged	  HDAC1	  wt	  and	  Aurora	  phospho	  mutants.	  Nocodazole	  was	  added	  for	  16	  hours	  and	  cells	  were	  collected	  by	  mitotic	  shake-­‐off.	  A.	  Samples	  were	  then	  analyzed	  by	  western	  blot	  with	  the	  indicated	   antibodies.	   Cyclin	   B1	  was	   used	   as	  marker	   of	  mitosis,	   total	  Histone	   3	   and	   vinculin	   as	   loading	   control.	  Densitometric	  analysis	  (B)	  was	  performed	  using	  Image	  J.	  Values	  were	  reported	  as	  fold	  change	  versus	  HDAC1	  wt.	  The	  experiment	  was	  done	  only	  once,	  thus	  no	  statistic	  analysis	  is	  included.	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specific	   histone	   lysine	   substrates,	   such	   as	   K9,	   whereas	   the	   HDAC1	   S406E	  mimetic	  mutant	  seems	  to	  fail	  to	  completely	  deacetylate	  its	  substrates.	  
	  
Expression	   of	   HDAC1	   Aurora-­‐phospho	   mutants	   does	   not	   alter	   cellular	  
proliferation	   and	   colony-­‐forming	   ability	   compared	   to	   HDAC1	  wild	   type	  
cells	  Many	   studies	   assign	   to	  HDAC1	  a	  pivotal	   role	   in	   cellular	  proliferation,	   cell	   cycle	   and	  apoptosis	  [21,22,87,89].	  To	   evaluate	   whether	   Aurora-­‐dependent	   phosphorylation	   of	   HDAC1	   influences	   the	  proliferation	  potential	  and	  clonogenicity	  of	  cells,	  growth	  curves	  and	  colony	   forming	  assays	  were	  performed.	  For	  the	  growth	  curve	  experiments,	  HeLa	  and	  MEF	  HDAC1	  KO	  cells	   were	   stably	   infected	   with	   flag	   tagged	   HDAC1	   wt,	   HDAC1	   S406A	   and	   HDAC1	  S406E	   constructs	   and	  plated	   in	   a	   96-­‐well	   plate	   (1500	   cells/well).	   Cell	   viability	  was	  measured	   every	   24	   hours	   for	   4	   days	   by	   CellTiter-­‐Glo®	   Luminescent	   Cell	   Viability	  Assay	  using	  quantitation	  of	  the	  ATP	  present	  as	  indicator	  of	  metabolically	  active	  cells.	  The	   graph	   in	   Figure	   16A-­‐C	   shows	   that	   overexpression	   of	   HDAC1	   Aurora-­‐phospho	  mutants	   did	   not	   affect	   cell	   proliferation	   at	   none	   of	   the	   time	   points	   considered.	  Western	  blots	  were	  performed	  to	  evaluate	  the	  efficiency	  of	  the	  infection	  (Figure	  17B-­‐D).	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Figure	  16.	  HDAC1	  Aurora-­‐dependent	  phosphorylation	  does	  not	  affect	  cellular	  proliferation	  
A-­‐C.	  HeLa	  cells	  or	  MEF	  HDAC1	  KO	  were	  stably	  infected	  with	  flag-­‐tagged	  HDAC1	  wt	  and	  Aurora	  phospho	  mutants.	  10,000	   cells	   were	   plated	   in	   24-­‐well	   plates	   and	   luminescence	   (as	   indicator	   of	   cell	   viability)	   were	  measured	   by	  CellTiter-­‐Glo®	  every	  24	  hours	  for	  4	  days.	  The	  fold	  increases	  of	  HDAC1	  construct	  compared	  to	  HDAC1	  wt	  (HeLa)	  or	  empty	   (MEF	  HDAC1	  KO)	  are	  reported	   for	  every	   time	  point.	  The	  average	  of	   three	   independent	  experiments	  was	  reported;	   the	  significance	  was	  calculated	  by	   two-­‐way	  ANOVA	  algorithm,	  standard	  error	  (SEM)	  was	   indicated	  by	  the	   error	   bars.	  B-­‐D.	  Western	   blot	   are	   also	   reported	   to	   check	   the	   over	   expression	   of	   the	   flag-­‐tagged	   constructs.	  Vinculin	  is	  used	  as	  loading	  controls.	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Human	   HDAC1	   Aurora	   phospho-­‐mutants	   differentially	   rescue	   the	  
phenotype	  of	  zebrafish	  hdac1	  morphant	  embryos	  compared	  to	  wild	  type	  
HDAC1	  	  Having	   characterized	   the	   biochemistry	   of	   the	   Aurora-­‐mediated	   phosphorylation	   of	  HDAC1,	   we	   searched	   for	   a	   biological	   read-­‐out.	   Zebrafish	   is	   a	   suitable	   model	   to	  investigate	   the	   effects	   and	   seek	   for	   a	   phenotype	   for	   HDAC1	   Aurora-­‐driven	  phosphorylation.	   In	   zebrafish	   a	   gene	   encoding	   HDAC2	   is	   not	   present,	   thereby	  overcoming	   the	   compensation	   mechanism	   that	   occurs	   in	   many	   cellular	   systems	  between	   HDAC1	   and	   HDAC2	  when	   one	   of	   the	   two	   proteins	   is	   depleted	   [21,22,87].	  Moreover,	  many	  studies	  have	  pointed	  to	   the	  crucial	  role	  of	  HDAC1	  during	  zebrafish	  development,	  in	  particular	  in	  the	  nervous	  system,	  the	  retina	  and	  the	  optic	  stalk	  [109].	  	  We	   used	   zebrafish	   development	   as	   a	  model	   and	   set	   up	   the	   following	   experimental	  approach:	  zebrafish	  embryos	  were	  injected	  right	  after	  fertilization	  with	  scramble	  or	  hdac1	  morpholino	   in	   the	  presence	  or	  absence	  of	   specific	  mRNAs	  codifying	  hHDAC1	  wt,	  S406A	  or	  S406E	  to	  evaluate	  the	  rescuing	  potential	  of	  the	  different	  Aurora	  mutants	  compared	  to	  wild	  type	  hHDAC1	  (human	  HDAC1).	  We	  observed	  that	  the	  injection	  of	  a	  scramble	   morpholino	   (negative	   control)	   did	   not	   affect	   the	   morphology	   of	   72	   hpf	  (hours	   post	   fertilization)	   embryos	   and	   the	   expression	   level	   of	   HDAC1	   protein	  compared	  to	  non-­‐injected	  fish	  (Figure	  18A).	  On	  the	  contrary,	  as	  already	  known	  [114],	  MO-­‐hdac1	   injected	   embryos	   displayed	   multiple	   developmental	   and	   morphological	  defects	  due	  to	  the	  absence	  of	  HDAC1:	  reduced	  head	  size	  (hd),	  absent	   jaw	  (j),	  curled	  down	  tail	   (ct);	  moreover,	  a	  pericardial	  edema	  (pe)	  was	  clearly	  visible.	  Also	  pectoral	  fins	   (pf)	  were	  missing,	  otoliths	   (*)	  were	  smaller	  and	  close	   together	  and	  melanocyte	  migration	  was	  defective.	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Figure	   18.	   HDAC1	   Aurora	   phospho-­‐mutants	   differentially	   rescue	   the	   phenotype	   of	   zebrafish	   hdac1	  
morphant	  embryos	  compared	  to	  wild	  type	  HDAC1	  
A.	   Lateral	   and	   dorsal	   overviews	   of	   indicated	   zebrafish	   embryos	   at	   72	   hours	   post	   fertilization	   (hpf).	   Arrows	  highlight	  morphological	  differences	  between	  embryos.	  hd:	  head,	  m:	  head	  melanocytes,	  j:	  jaw,	  e:	  eye,	  pe:	  pericardial	  edema,	  y:	  yolk,	  pf:	  pectoral	  ns,	  t:	  tail,	  ct:	  curled	  down	  tail,	  *:	  otoliths.	  B.	  Western	  blot	  analysis	  of	  protein	  extracts	  from	  the	   indicated	  embryos	  collected	  at	  72	  hpf.	  The	  anti-­‐human	  HDAC1	  recognizes	  also	  zebrafish	  HDAC1.	  Anti-­‐Histone3	  (H3)	  antibody	  was	  used	  as	  a	  loading	  control.	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edema,	   proper	   melanocyte	   distribution	   and	   an	   outline	   of	   pectoral	   fins	   are	   visible.	  Interestingly,	   the	  human	  Aurora	  phospho-­‐null	   S406A	  mutant	  only	  partially	   rescued	  essential	   features	   of	   the	  morphant	   phenotype.	   In	   fact,	   although	   reduced	   head	   size,	  absence	   of	   pectoral	   fins	   and	   cell	  migration	   defects	   observed	   in	  morphant	   embryos	  still	  persisted,	  a	  proper	  body	  axis	  and	  pericardial	  edema	  were	  recovered.	  Moreover,	  the	  eye	  structure	  was	  less	  affected	  compared	  to	  hdac1	  morpholino	  embryos.	  Notably,	  all	   the	   body	   structures	   showed	   a	   striking	   developmental	   delay,	   as	   indicated	   by	   the	  late	  migration	  of	  the	  head	  melanocytes	  and	  yolk	  reabsorption.	  About	  56%	  of	  HDAC1	  S406A	   injected	   embryos	   showed	   a	   wild-­‐type-­‐like	   phenotype.	   Conversely,	   the	  expression	  of	  the	  human	  phospho-­‐mimetic	  HDAC1	  S406E	  was	  not	  able	  to	  rescue	  the	  phenotype	  in	  a	  hdac1	  morpholino	  background:	  strong	  defects	  in	  the	  development	  of	  the	  head	  and	   the	  eye	  were	  present,	  pericardial	  edema	  was	  not	   reabsorbed	  and	   jaw	  and	  pectoral	  fins	  failed	  to	  form.	  Furthermore,	  there	  was	  no	  recovery	  in	  the	  body	  axis:	  a	  curled	  down	  tail	  was	  present	  and	  a	  random	  distribution	  of	  melanocytes	  was	  visible,	  particularly	  in	  the	  head.	  About	  70%	  of	  the	  HDAC1	  S406E	  injected	  embryos	  had	  a	  MO	  hdac1-­‐like	  phenotype.	  Figure	  18B	  shows	  the	  corresponding	  western	  blot	  to	  verify	  the	  knock	  down	  of	  zebrafish	  endogenous	  hdac1	  (zbHDAC1)	  and	  the	  expression	  of	  human	  HDAC1	   proteins	   (hHDAC1):	   the	   complete	   depletion	   of	   the	   endogenous	   zbHDAC1	  protein	   upon	   hdac1	  MO	   injection	   is	   visible	   in	   lane	   3;	   lanes	   4,	   5	   and	   6	   display	   the	  expression	  of	  the	  injected	  human	  proteins	  in	  a	  hdac1	  MO	  background.	  Taken	  together	  these	  results	  indicated	  that	  a	  proper	  balance	  of	  the	  Aurora-­‐driven	  phosphorylation	  of	  HDAC1	   is	   critical	   for	   the	  maintenance	   of	   a	   proper	   proliferative	   and	   developmental	  plan	  in	  a	  complex	  organism.	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Aurora	  kinases	  phosphorylate	  human	  HDAC1	  in	  zebrafish	  embryos	  Using	  the	  BT15	  antibody	  (produced	  at	  IFOM-­‐IEO	  Campus)	  that	  specifically	  recognizes	  serine	   406	   phosphorylation	   on	   HDAC1	   (see	   Figure	   11,	   Introduction),	   we	   verified	  whether	   the	   orthologs	   of	   the	   human	   Aurora	   kinases	   were	   able	   to	   phosphorylate	  hHDAC1	   also	   in	   zebrafish	   embryos.	   Thus,	   zebrafish	   embryos	   were	   injected	   with	  hdac1	  morpholino	  alone	  or	   in	   combination	  with	  hHDAC1	  Aurora	  phospho	  mutants,	  collected	  at	  24	  hpf	  and	  immunostained	  with	  BT15	  antibody.	  DAPI	   and	   p-­‐S10H3	   staining	   were	   also	   performed	   as	   control	   of	   the	   cell	   cycle	   stage	  (chromatin	   state)	   and	   the	   mitotic	   phase,	   respectively.	   Flag	   antibody	   was	   used	   to	  recognize	   cells	   in	   which	   flag-­‐tagged	   hHDAC1	   Aurora	   phospho	   mutants	   were	  distributed	  upon	  injection.	  Indeed,	  although	  the	  constructs	  were	  injected	  at	  one-­‐cell	  stage	  right	  after	   fertilization,	  HDAC1	  mRNAs	  may	  have	  randomly	  spread	  during	  cell	  division,	  hence	  producing	  chimerae.	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  
Figure	  19.	  Human	  and	  zebrafish	  HDAC1	  differ	  of	  4	  mismatches	  in	  the	  BT15	  epitope	  The	   BT15	   epitope	   recognizing	   the	   KRISI	   Aurora	   consensus	  motives	   of	   HDAC1	   is	   reported.	   The	   non-­‐conserved	  residues	  between	  human	  and	   zebrafish	  HDAC1	  are	   shown	   respectively	   in	   green	   and	  pink.	  The	   amino	   acids	   are	  indicated	  according	  to	  the	  universal	  one	  letter	  code.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  As	   shown,	   in	   embryos	   injected	   with	   a	   scramble	   morpholino	   there	   were	   no	   BT15	  positive	   cells	   probably	   because	   human	   and	   zebrafish	   HDAC1	   protein	   differ	   by	   a	   4	  
…VQMQAIPEDAVQEDSGDE-EDDPDKRISIRAHDKRIACDEEFSDSEDEGQGGRRNAANYKKPKR 
…VQMQAIPEDAIPEESGDEDEDDPDKRISICSSDKRIACEEEFSDSDEEGEGGRKNSSNFKKAKR 
397 415  406 
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Figure	  20.	  Aurora	  kinases	  phosphorylate	  hHDAC1	  Aurora	  phospho	  mutants	  in	  zebrafish	  embryos	  












	   67	  
Overexpression	   of	   human	   HDAC1	   Aurora	   phospho-­‐mutants	   does	   not	  
result	  in	  any	  morphological	  defects	  in	  zebrafish	  embryos	  Our	   previous	   experiments	   demonstrated	   that,	   upon	   injection	   in	   zebrafish	   embryos	  together	   with	   hdac1	   MO,	   expression	   of	   human	   HDAC1	   Aurora	   phospho-­‐mutants	  resulted	  in	  different	  phenotypes.	  In	  particular,	  human	  HDAC1	  wt	  completely	  rescued	  the	  morphological	  defect	  induced	  by	  depletion	  of	  hdac1	  (Figure	  18),	  whereas	  HDAC1	  S406A	  mutant	  caused	  a	  marked	  delay	  in	  the	  development	  of	  the	  embryos,	  and	  HDAC1	  S406E	   strongly	   impaired	   the	   formation	   and	   growth	   of	   many	   embryos	   body	  structures.	   Therefore,	   we	   overexpressed	   human	   HDAC1	   wt,	   S406A	   and	   S406E	   to	  evaluate	   their	   impact	   on	   expression	   of	   the	   endogenous	   zbHDAC1	   and	   on	   the	  morphology	  of	   the	  embryos.	  Therefore,	  hHDAC1	  wt	  or	   its	  Aurora	  phospho	  mutants	  were	  injected	  right	  after	  fertilization	  in	  zebrafish	  embryos	  and	  72hpf	  embryos	  were	  then	  collected.	  	  Figure	   21A	   clearly	   displays	   that	   overexpression	   of	   human	   HDAC1	   wt,	   as	   well	   as	  HDAC1	   S406A	   and	   S406E	   mutants	   did	   not	   perturb	   the	   development	   and	   the	  morphology	  of	   the	   injected	  embryos,	  which	  perfectly	  phenocopied	   their	  un-­‐injected	  counterparts.	   Furthermore,	   the	   related	   western	   blot	   (Figure	   21B)	   showed	   that	  expression	   of	   the	   HDAC1	   Aurora	   phospho-­‐mutants	   did	   not	   affect	   the	   endogenous	  zbHDAC1	  protein	  level.	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Figure	  21.	  Overexpression	  of	  hHDAC1	  Aurora	  phospho-­‐mutants	  does	  not	  impact	  on	  developing	  zebrafish	  
embryos	  
A.	  Lateral	  and	  dorsal	  overviews	  of	  indicated	  zebrafish	  embryos	  at	  72	  hours	  post	  fertilization	  (hpf).	  B.	  Western	  blot	  analysis	   of	   protein	   extracts	   from	   the	   indicated	   embryos	   collected	   at	   72	   hpf.	   The	   anti-­‐human	   HDAC1	   does	   not	  recognize	  zebrafish	  HDAC1.	  Anti-­‐actin	  antibody	  was	  used	  as	  a	  loading	  control.	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Human	  HDAC1	  Aurora	  phospho-­‐mutants	  do	  not	   rescue	   the	  depletion	  of	  
the	  G2-­‐M	  population	  in	  hdac1	  morphant	  zebrafish	  embryos	  In	  light	  of	  the	  different	  effects	  on	  the	  zebrafish	  embryos	  development	  upon	  injection	  of	  HDAC1	  Aurora-­‐phospho	  mutants,	  we	  monitored	  cell	  cycle	  progression	  in	  embryos	  expressing	  hdac1	  MO	  alone	  or	   in	  combination	  with	  human	  HDAC1	  Aurora-­‐phospho	  mutants	  and	   in	  control	  embryos.	  Thus,	  we	  measured	   the	  DNA	  content	  of	   cells	   from	  24,	   48	   and	   72	   hpf	   embryos	   by	   PI	   staining	   and	   fluorescence-­‐activated	   cell	   sorting	  (FACS)	   analyses.	   Comparing	   cell	   populations	   of	   embryos	   heads	   between	   scramble	  and	   hdac1	   morphant	   embryos,	   we	   found	   a	   high	   and	   significant	   reduction	   of	  approximately	   50%	   in	   the	   G2-­‐M	   populations	   in	   each	   of	   the	   three	   time	   points	  considered	  (Figure	  22).	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Figure	  22.	  Human	  HDAC1	  (hHDAC1)	  Aurora	  phospho-­‐mutants	  cause	  the	  depletion	  of	  the	  G2-­‐M	  population	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G2-­‐M	   phase	   increased	   by	   at	   least	   20%	   at	   72	   hpf.	   Moreover,	   heads	   of	   embryos	   co-­‐injected	   with	   hdac1	   MO	   and	   human	   HDAC1	   S406A	   displayed,	   compared	   to	   the	  control,	  a	  significant	  reduction	  of	  almost	  40%	  in	  the	  G2-­‐M	  population	  only	  at	  48	  hpf.	  	  	  Taken	   together,	   these	   results	   suggest	   that	   HDAC1	   Aurora	   phospho	   mutants	  compromise	  the	  accurate	  cell	  cycle	  progression	   in	  the	  morphant	  embryos,	   failing	  to	  restore	   reduction	   in	   the	   G2-­‐M	   cell	   population,	   which	   most	   likely	   leads	   to	  developmental	  and	  morphological	  defects.	  	  	  
Human	   HDAC1	   Aurora-­‐phospho	   mutants	   regulate	   global	   histone	  
acetylation	  in	  the	  developing	  zebrafish	  embryo	  Our	   findings	  with	   the	   in	   vitro	   histone	   assay	   led	   to	   the	   hypothesis	   that	   the	   Aurora-­‐dependent	   phosphorylation	   of	   HDAC1	   is	   important	   in	   controlling	   the	   deacetylase	  activity	   of	   the	   enzyme:	   in	   particular	   we	   found	   that	   the	   Aurora	   phospho-­‐mimetic	  mutant	  HDAC1	  S406E	  was	  less	  efficient	  in	  deacetylating	  labeled	  histones	  compared	  to	  HDAC1	  wt	  (Figure	  14).	  Thus,	   considering	   also	   the	   morphological	   data	   described	   in	   developing	   zebrafish	  embryos	   injected	   with	   hdac1	   MO	   alone	   or	   in	   combination	   with	   hHDAC1	   Aurora	  phospho	   mutants	   (Figure	   18),	   we	   asked	   whether	   the	   differences	   emerging	   in	   the	  phenotype	   of	   hHDAC1	   wt,	   hHDAC1	   S406A	   and	   S406E	   embryos	   could	   be	   partially	  ascribed	  to	  a	  differential	  ability	  of	   the	  Aurora	  phospho	  mutants	  to	  deacetylate	  their	  substrates.	  	  To	   this	  end,	   immunohistochemistry	   (IHC)	  experiments	  were	  carried	  out	  on	  embryo	  sections	   testing,	   with	   a	   pan-­‐acetylated	   antibody,	   the	   deacetylating	   potential	   of	  hHDAC1	  Aurora	  phospho-­‐mutants	  in	  vivo.	  	  72	  hpf	  embryos	  were	  collected,	   included	   in	  agarose	  and	   then	  embedded	   in	  paraffin	  and	   sliced	   with	   microtome.	   Sectiones	   of	   hdac1	   morphant	   embryos	   or	   embryos	  
	  72	  
injected	  with	  MO+	  hHDAC1	  wt,	  S406A	  or	  S406E	  mutants	  were	  immunostained	  with	  a	  acetylated-­‐histone	  antibody	  and	  the	  acetylation	  levels	  in	  the	  eyes	  were	  compared	  to	  those	  of	  control	  embryos.	  Haematoxylin	  staining	  was	  also	  performed	  to	  recognize	  cell	  nuclei.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
Figure	  23.	  hHDAC1	  Aurora-­‐dependent	  phosphorylation	  affects	  histone	  acetylation	  in	  vivo	  Immunohistochemistry	   staining	   with	   haematoxylin	   (blue)	   and	   anti-­‐acetylated	   histone	   antibody	   (brown)	   of	  sections	   obtained	   by	   72	   hpf	   embryos	   injected	   at	   one-­‐cell	   stage	   with	   scramble	   MO,	   hdac1	   MO	   (A),	   hdac1	  MO+hHDAC1	  wt	  (B),	  hdac1	  MO+hHDAC1	  S406A	  (C),	  hdac1	  MO+hHDAC1	  S406E	  (D).	  The	  percentage	  of	  acetylated	  cells	  was	  calculated	  using	  Aperio	  ImageScope	  software	  and	  is	  reported	  for	  every	  sample.	  Although	  present	  in	  the	  graph,	   image	  taken	  from	  scramble	  MO	  is	  missing	  because	  of	   technical	  problems.	  The	  experiment	  was	  done	  only	  once,	  thus	  no	  statistic	  analysis	  is	  included.	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The	  results	  are	  shown	  in	  Figure	  23:	  as	  expected,	  knock	  down	  of	  endogenous	  hdac1	  in	  morphant	  embryos	  increased	  the	  percentage	  of	  positive	  (acetylated)	  cells	  compared	  to	  scramble	  MO	  injected	  embryos	  (A);	   interestingly,	  we	  observed	  the	  same	  trend	   in	  the	   eyes	   of	   embryos	   injected	  with	   hdac1	  MO+	   hHDAC1	   S406E	   (D),	   suggesting	   that	  also	   in	   a	   in	   vivo	   model	   the	   Aurora	   phospho-­‐mimetic	   form	   of	   HDAC1	   failed	   to	  deacetylate	   its	   substrates.	  Conversely,	  measuring	   the	  percentage	  of	  positive	   cells	   in	  control	  embryos	  and	  embryos	  co-­‐injected	  with	  hdac1	  MO	  and	  hHDAC1	  wt,	  very	  slight	  differences	  were	  detected,	  indicating	  that	  hHDAC1	  wt	  mRNA	  was	  able	  to	  restore	  the	  acetylation	  level	  in	  72	  hpf	  embryos	  eyes	  (B).	  Additionally,	  embryos	  expressing	  hdac1	  MO	  together	  with	  hHDAC1	  S406A	  mutant	  exhibited	  compared	  to	  the	  control,	  higher	  levels	  of	  eye	  acetylation,	  even	  though	  the	  percentage	  of	  positive	  cells	  was	  still	  much	  lower	   than	   those	   in	   morphant	   embryos	   (C).	   This	   result	   is	   in	   line	   with	   the	  morphological	   data	   that	   shows	   for	   HDAC1	   Aurora	   phospho-­‐null	   mutant	   an	  intermediate	  phenotype	  between	  morphant	  and	  rescued	  embryos.	  The	   preliminary	   IHC	   experiment	   indicates	   that	   HDAC1	   Aurora-­‐dependent	  phosphorylation	   is	   involved	   in	   the	   control	   of	   the	   catalytic	   activity	   of	   the	   enzyme	  regulating	  global	  histone	  acetylation	  levels	  in	  developing	  zebrafish	  embryos.	  	  	  
Human	   HDAC1	   Aurora	   phospho-­‐mutants	   epigenetically	   modulate	  
acetylation	   of	   neurogenic	   regulatory	   genes	   throughout	   the	   zebrafish	  
developing	  CNS	  Harrison	  and	  colleagues	  identified,	  via	  transcriptome	  comparative	  analysis	  of	  hdac1-­‐deficient	   and	   control	   zebrafish	   embryos,	   a	   small	   subset	   of	   genes	   that	   specifically	  exhibit	  Hdac1-­‐dependent	  expression	   from	  early	  neurogenesis	  onwards	   [112].	  Thus,	  we	   asked	   whether	   HDAC1	   Aurora	   mutants	   exert	   their	   regulation	   by	   an	   epigenetic	  mechanism.	   To	   verify	   this	   hypothesis,	   we	   performed,	   on	   heads	   of	   72	   hpf	   embryos	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injected,	  at	  one-­‐cell	  stage,	  with	  hdac1	  MO	  alone	  or	  in	  combination	  with	  hHDAC1	  wt,	  S406A	   or	   S406E,	   a	   chromatin	   immunoprecipitation	   (ChIP)	   experiment	   with	   anti-­‐acetylated	  lysine	  H3K27	  antibody.	  Since	  HDAC1	  lacks	  a	  DNA-­‐binding	  domain	  and	  as	  it	  is	  not	  directly	  associated	  with	  chromatin,	  we	  did	  not	  use	  an	  anti-­‐HDAC1	  antibody,	  but	  assumed	   that	   possible	   differences	   in	   H3K27	   acetylation	   levels	   could	   be	   due	   to	   the	  injection	  of	  the	  HDAC1	  Aurora	  phospho-­‐mutant.	  The	  ChIP	  experiment	  was	  coupled	  to	  quantitative	   PCR	   to	   evaluate	   the	   enrichment	   in	   the	   acetylation	   of	   the	   promoter	   of	  selected	   genes	   compared	   to	   their	   input.	   A	   possible	   enrichment	   in	   the	   H3K27	  acetylation	  level	  of	  the	  promoter	  can	  be	  an	  indirect	  proof	  of	  the	  binding	  of	  HDAC1	  to	  the	  region	  considered.	  The	  genes	  used	  for	  the	  quantitative	  analysis	  were	  chosen	  from	  a	   list	   of	   genes	   involved	   in	   zebrafish	   developing	   CNS	   and	   retina,	   whose	   expression	  significantly	  changed	  upon	  hdac1	  ablation	  published	  by	  Harrison	  and	  colleagues.	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Figure	   24.	   hHDAC1	   Aurora-­‐dependent	   phosphorylation	   plays	   a	   role	   in	  modulating	   acetylation	   of	   genes	  
involved	  in	  developing	  zebrafish	  CNS	  	  	  Chromatin	   immunoprecipitation	   (ChIP)	   analysis	   of	   H3K27	   acetylated	   cis-­‐regulatory	   regions	   of	   zbHDAC1-­‐regulated	  genes.	  Embryos	  were	   injected	  with	  scramble	  MO	  or	  hdac1	  MO	  alone	  or	   in	  combination	  with	  hHDAC1	  aurora	  phospho	  mutants	  and	  collected	  at	  72	  hpf.	  Chromatin	  was	  immunoprecipitated	  with	  anti-­‐acH3K27	  antibody	  and	   control	   IgG	   and	   DNA	   content	   analyzed	   by	   q-­‐PCR.	   Experiment	   done	   only	   once,	   thus	   no	   statistic	   analysis	   is	  included.	  Negative	  control	  was	  not	  included.	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Discussion	  
	  HDAC1	  and	  HDAC2	  are	  believed	  to	  be	   the	  master	  regulators	  of	  chromatin	  structure	  and	   gene	   expression	   and	   are	   also	   deeply	   involved	   in	   cellular	   proliferation,	   the	   cell	  cycle,	   and	   apoptosis	   [21,22,87,89].	   However,	   the	   molecular	   pathways	   in	   which	  HDAC1	  and	  HDAC2	  are	  involved	  during	  cell	  cycle	  progression	  remain	  unclear.	  	  HDAC1	  and	  HDAC2	  are	  targets	  of	  a	  complex	  code	  of	  post-­‐translational	  modifications	  (PTMs)	   [58].	   Because	   PTMs	   influence	   enzymatic	   activity	   and	   complex	   formation	   of	  the	  two	  proteins,	  it	  is	  reasonable	  to	  assume	  that	  the	  key	  to	  dissect	  HDAC1	  and	  HDAC2	  functions	  lies	  in	  understanding	  their	  PTM	  code.	  Among	  the	  various	  PTMs	  that	  occur	  on	  HDAC1	  and	  HDAC2,	  phosphorylation	  is	  the	  most	  intensively	  studied:	  HDAC1	  and	  HDAC2	   can	   be	   phosphorylated	   by	   the	   casein	   kinase	   II	   (CKII).	   The	   CKII-­‐dependent	  phosphorylation	  enhances	  the	  deacetylase	  activity	  and	  the	  transcriptional	  repression	  as	  well	  as	  the	  interaction	  with	  multisubunit	  complex	  partners	  [38,61]	  [63].	  	  Our	  lab	  identified	  a	  new	  mitotic	  phosphorylation	  of	  HDAC1	  and	  HDAC2.	  Our	  previous	  findings	  demonstrated	  that	  the	  two	  enzymes	  are	  phosphorylated	  specifically	  in	  pro-­‐metaphase	  by	  Aurora	  kinases	  A	  and	  B	  (see	  Figure	  11,	   Introduction).	  Other	  enzymes	  critically	  involved	  in	  mitosis,	  such	  as	  the	  phosphatase	  Cdc25B	  [188],	  show	  the	  same	  phosphorylation	  profile,	   suggesting	   that	  HDAC1	   and	  HDAC2	  phosphorylation	  might	  be	  a	  signal	  to	  switch	  on/off	  some	  specific	  functions.	  	  As	  mentioned	  above,	  HDAC1	  plays	  a	  major	  role	   in	  controlling	  cell	  cycle	  progression	  and	  cell	  proliferation	  and	  has	  been	  found	  deregulated	   in	  many	  cancer	  cell	   lines	  and	  tissues.	  Moreover,	   Senese	   et	   al.	   proved	   that	   the	   absence	   of	   HDAC1	   can	   arrest	   cells	  either	  at	  the	  G1	  phase	  of	  the	  cell	  cycle	  or	  at	  the	  G2/M	  transition,	  resulting	  in	  the	  loss	  of	  mitotic	  cells,	  cell	  growth	  inhibition,	  and	  an	  increase	  in	  apoptosis,	  whereas	  HDAC2	  knockdown	   showed	   no	   effect	   on	   cell	   proliferation	   unless	   HDAC1	  was	   concurrently	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knocked	   down	   [22].	   Thus,	   we	   focused	   at	   understanding	   the	   biological	   role	   of	   the	  Aurora-­‐dependent	  phosphorylation	  of	  HDAC1.	  In	   accordance	   with	   the	   in	   vivo	   evidence	   (Figure	   8-­‐11),	   our	   in	   vitro	   kinase	   assay	  confirms	   the	   affinity	   of	   the	   Aurora	   A	   and	   B	   kinases	   for	   HDAC1	   (Figure	   14)	   also	  suggesting	   a	   direct	   interaction	   between	   the	   two	   kinases	   and	   the	   deacetylating	  enzyme	  	  (Figure	  12).	  	  Given	  the	  well-­‐established	  role	  of	  CKII	  in	  phosphorylating	  HDAC1,	  we	  asked	  whether	  CKII	   was	   responsible	   for	   making	   the	   Aurora	   phosphorylation	   sites	   available.	   We	  found	   instead	   that	   the	   activity	   of	   CKII	   is	   not	   required	   for	   mitotic	   hyper-­‐phosphorylation	   of	   HDAC1	   by	   Aurora	   kinases	   (Figure	   13).	   The	   absence	   of	  phosphorylation	   of	   HDAC1	   on	   serine	   421/423	   does	   not	   impair	   its	   mitotic	  phosphorylation,	   since	   the	  HDAC1	  2S	  mutant	   is	  phosphorylated	   in	  mitosis	   at	   levels	  comparable	   to	   the	  wild	   type,	   thus	   excluding	   a	   possible	   cross-­‐talk	   between	   the	   two	  kinases	  and	  a	  possible	  hierarchy	  in	  the	  PTM	  code.	  	  It	   is	   also	   known	   that	   the	   abolition	   of	   CKII-­‐dependent	   phosphorylation	   of	   HDAC1	  abrogates	   its	   catalytic	   activity	   and	   dramatically	   reduces	   the	   binding	   with	   HDAC2,	  RbAP48,	   Sin3a,	   CoREST	   and	   MTA-­‐2	   [38].	   We	   thus	   asked	   whether	   the	   Aurora-­‐dependent	  phosphorylation	  affects	  the	  deacetylating	  potential	  of	  HDAC1,	  acting	  as	  a	  fine	   modulator	   in	   a	   specific	   time	   interval	   of	   cell	   cycle.	   We	   found	   that	   neither	   the	  phospho-­‐null	   nor	   the	   phospho-­‐mimetic	   mutants	   of	   HDAC1	   are	   deficient	   in	   their	  ability	   to	  bind	  known	  partners	   such	  as	  RbAP48	  or	  endogenous	  HDAC2	  (Figure	  14).	  However,	  we	  plan	   to	   test	   also	   the	   interaction	  between	  HDAC1	  Aurora	  mutants	   and	  other	  multiprotein	   complex	   proteins	   (Sin3a,	   CoREST	   and	  MTA-­‐2).	   On	   the	   contrary,	  concerning	   the	  effects	  on	  the	  deacetylating	  activity,	   the	  phospho-­‐mimetic	  mutant	  of	  HDAC1	  displays	   a	  partial	   reduction	  on	   the	   catalytic	  potential	   compared	   to	   the	  wild	  type,	  even	  if	  its	  deacetylating	  ability	  is	  not	  completely	  abrogated	  as	  in	  the	  case	  of	  the	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CKII	   phospho-­‐null	  mutant	   (HDAC1	   2S).	   The	   reduced	   catalytic	   ability	   of	   the	  mutant	  HDAC1	   S406E	   is	   unlikely	   to	   be	   due	   to	   improper	   folding	   of	   the	   protein,	   since	   its	  binding	  with	   other	   partners	   is	   not	   affected.	  One	  possible	   explanation	   could	   be	   that	  mitotic	   phosphorylation	   of	   HDAC1	   promotes	   the	   association	   with	   other,	   unknown	  partners	  that	  modulate	  the	  affinity	  of	  the	  enzyme	  for	  its	  substrates.	  	  Moreover,	  it	  was	  already	   reported	   that	   during	   mitosis	   HDAC1	   is	   excluded	   from	   chromatin,	   even	   if	  global	   deacetylation	   activity	   is	   maintained	   [189].	   Phosphorylation	   adds	   a	   negative	  charge	   to	   the	   surface	   of	   HDAC1,	   which	   could	   increase	   the	   electrostatic	   repulsion	  between	  HDAC1	  and	  the	  negatively	  charged	  DNA.	  So	  we	  speculate	  that	  the	  presence	  of	  the	  negative	  charge	  in	  the	  HDAC1	  S406E	  mutant	  could	  facilitate	  the	  displacement	  of	   the	  enzyme.	  Further	  experiments	  are	  required	  to	  corroborate	  this	  hypothesis.	  To	  this	  aim	  we	  generated	  GFP-­‐HDAC1	  fusion	  proteins	  that	  will	  be	  used	  to	  perform	  live	  cell	  imaging	  by	  time	  lapse	  microscopy	  to	  track	  the	  localization	  kinetics	  of	  HDAC1	  wild	  type,	  phospho-­‐null	  and	  phospho-­‐mimetic	  proteins.	  We	   also	   checked	   the	   activity	   of	   the	   different	   HDAC1	   mutants	   directly	   in	   vivo,	  analyzing	   by	   western	   blot	   the	   acetylation	   status	   of	   histone	   H3K9	   (Figure	   15).	   Our	  preliminary	   in	  vivo	  data	  support	  the	   in	  vitro	   findings:	  indeed,	  we	  observed	  a	  slightly	  higher	   H3K9	   acetylation	   upon	   overexpression	   of	   the	   less	   active	   S406E	   mutant,	  whereas	   overexpression	   of	   HDAC1	   S406A	   mildly	   reduces	   histone	   acetylation	  compared	   to	   the	   control,	   probably	   because	   its	   activity	   cannot	   be	   modulated	   by	  Aurora-­‐dependent	  phosphorylation.	  Thus	  it	  is	  always	  active	  also	  in	  mitosis.	  	  Our	   preliminary	   data	   suggest	   that	   there	   might	   be	   an	   effect	   of	   S406-­‐HDAC1	  phosphorylation	  on	  its	  catalytic	  activity	  also	   in	  vivo.	  Nevertheless,	  our	  growth	  curve	  and	  colony	  forming	  assay	  experiments	  (performed	  both	  in	  the	  presence	  and	  absence	  of	   the	   endogenous	   HDAC1)	   do	   not	   reveal	   any	   differences	   among	   the	   two	   Aurora-­‐
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phospho	   mutants	   in	   terms	   of	   proliferation	   potential	   and	   clonogenicity	   of	   the	   cells	  compared	  to	  the	  wild	  type	  protein	  (Figure	  16,	  17).	  	  The	   finding	   that	   Aurora-­‐dependent	   phosphorylation	   of	   HDAC1	   does	   not	   induce	  dramatic	   effects	   on	   cellular	   phenotypes	   is	   not	   in	   contrast	   with	   what	   our	   group	  previously	   reported,	   where	   depletion	   of	   HDAC1	   (but	   not	   of	   HDAC2)	   caused	   an	  increase	   in	   apoptosis	   and	   proliferation	   defects	   [22];	   but	   rather	   confirms	   our	  hypothesis	  of	  a	  fine-­‐tuning	  role	  for	  HDAC1	  phosphorylated	  S406	  in	  proper	  cell	  cycle	  progression.	  	  A	  modest	  and	  only	  partial	  rescuing	  of	  a	  mitotic	  phenotype	  was	  already	  reported	  for	  phosphorylation	   of	   another	   protein	   involved	   in	   mitosis,	   the	   phosphatase	   Cdc25B	  [188].	  Cdc25B	   is	  phosphorylated	  by	  Aurora	  A	  at	   the	  G2/M	  transition	  on	  serine	  353	  [190],	  and	  this	  phosphorylation	  is	  inhibited	  when	  the	  G2/M	  DNA	  damage	  checkpoint	  is	   activated,	   probably	   as	   a	   consequence	   of	   Aurora	   A	   inactivation	   itself	   [191].	  Overexpression	   of	   Aurora	   A	   or	   Cdc25B	   wild	   type	   caused	   an	   override	   of	   the	   DNA	  damage	   checkpoint	   of	   89%	   and	   46%	   respectively,	   while	   the	   overexpression	   of	   the	  Cdc25B	   S353A	  mutant	   induced	   33%	   of	   override,	   and	   54%	  when	   coexpressed	  with	  Aurora	  A.	  These	  and	  our	  data	  suggest	  that	  mutations	  in	  a	  single	  phosphorylation	  site	  normally	  do	  not	  lead	  to	  a	  dramatically	  different	  phenotype	  compared	  to	  the	  wild	  type	  counterparts;	  furthermore,	  it	  should	  be	  considered	  that	  key	  cellular	  enzymes,	  such	  as	  HDAC1	  or	  Cdc25B	  phosphatase,	  possess	  very	  complex	  PTMs	  codes,	  and	  it	  is	  unlikely	  that	   a	   single	   modification	   event	   completely	   abrogates	   the	   protein’s	   functions.	  Nevertheless,	  these	  considerations	  do	  not	  imply	  that	  specific,	  point	  modifications	  are	  not	  significant.	  It	   has	   also	   to	  be	   taken	   into	   account	   that	   in	  many	   cellular	   systems,	   due	   to	   the	  well-­‐known	  compensation	  mechanism	  between	  HDAC1	  and	  HDAC2	   [192,193],	   depletion	  of	  HDAC1	  leads	  to	  an	  increased	  level	  of	  HDAC2	  protein	  and	  vice	  versa	  [21,192,193].	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Thus,	   it	   could	   be	   difficult	   to	   unravel	   the	   function	   of	   the	   Aurora-­‐dependent	  phosphorylation	  of	  HDAC1	  in	  the	  presence	  of	  HDAC2,	  and	  perhaps	  mammalian	  cells	  do	   not	   best	   suite	   towards	   the	   purpose	   of	   understanding	   the	   role	   of	   this	  phosphorylation.	  Furthermore,	   we	   reasoned	   that	   proliferation	   and	   differentiation	   are	   two	  interconnected	  pathways,	   especially	  during	  development,	  where	   every	   event	  of	   cell	  division	   must	   be	   strictly	   regulated	   in	   space	   and	   time	   to	   successfully	   complete	   the	  developmental	   plan.	   It	   is	   even	   true	   that	   also	   small	   delays	   in	   proliferation	   would	  produce	  dramatic	  effects	   in	   the	  context	  of	  an	  organism	  rather	   than	   in	   immortalized	  cell	   cultures.	  As	  such,	  we	  searched	   for	  an	   in	  vivo	  model	   to	   investigate	   the	  biological	  role	   of	   this	   mitotic	   phosphorylation	   of	   HDAC1,	   especially	   considering	   the	   crucial	  involvement	  of	  the	  enzyme	  in	  development.	  Zebrafish	  seemed	  to	  be	  a	  suitable	  model.	  Indeed,	  in	  zebrafish	  a	  perfectly	  coordinated	  and	  regulated	  cell	  cycle	  is	  the	  conditio	  sine	  qua	  non	  for	  the	  proper	  completion	  of	  the	  developmental	   program	   and	   even	   very	   slight	   perturbations	   are	   likely	   to	   have	   a	  dramatic	  impact.	  Unlike	  mammals,	  zebrafish	  do	  not	  possess	  two	  distinct	  HDAC1	  and	  HDAC2	   genes,	   but	   they	   only	   have	   one,	   which	   is	   more	   similar	   to	   human	   HDAC1	   in	  terms	   of	   amino	   acidic	   sequence.	   Moreover,	   the	   Aurora	   phosphorylation	   consensus	  site	   is	   highly	   conserved	   during	   the	   evolution	   between	   zebrafish	   and	   human.	   As	   in	  mammals,	  zbHDAC1	  (hdac1)	  has	  a	  pivotal	  role	  in	  development:	  hdac1	  mutants	  show	  abnormalities	   in	   the	   heart,	   retina,	   craniofacial	   cartilage	   and	   pectoral	   fins	   and	   have	  reduced	  proliferation	  in	  hindbrain	  [112,114,194,195].	  	  Our	   experimental	   approach	   consisted	   in	   knocking	   down	   the	   endogenous	   hdac1	   in	  zebrafish	  oocytes	  using	  the	  morpholino	  strategy,	  and	  reinserting	  the	  human	  HDAC1	  wild	   type	   and	   Aurora	   phospho	   mutants	   in	   order	   to	   observe	   possible	   different	  phenotypes	  during	  the	  development	  of	  the	  animal.	  While	  the	  human	  HDAC1	  wild	  type	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is	   able	   to	   rescue	   the	   phenotype	   of	   hdac1	   morphants	   at	   72	   hpf	   (hours	   post	  fertilization),	  the	  two	  phospho-­‐Aurora	  mutants	  show	  a	  different	  behavior	  (figure	  18).	  The	   phenotype	   of	   the	   phospho-­‐null	   S406A	   mutant	   injected	   embryos	   is	   not	  dramatically	  impaired	  but	  looks	  more	  as	  if	  it	  has	  a	  delay	  in	  development.	  It	  has	  been	  published	   that	  depletion	  of	  Aurora	  A	   in	  zebrafish	  causes	  growth	  retardation	  due	   to	  mitotic	  delay	  [196],	  so	   it	  may	  be	  that	   the	  phenotype	  observed	  upon	   injection	  of	   the	  HDAC1	  phospho-­‐null	  mutant	   is	   due	   to	   the	   absence	   of	   the	   kinase	   rather	   than	   a	   real	  effect	  of	  the	  phosphorylation	  on	  HDAC1.	  	  On	  the	  contrary,	  the	  embryos	  injected	  with	  the	   phospho-­‐mimetic	   S406E	   are	   deeply	   affected	   and	   show	   defects	   in	   development	  and	  proliferation,	  in	  particular	  of	  the	  eye	  and	  head,	  phenocopying	  the	  morphology	  of	  hdac1	   morphant	   or	   mutant	   in	   zebrafish	   embryos	   [114].	   Perhaps	   the	   decreased	  enzymatic	   activity	   of	   the	   phospho-­‐mimetic	   406E	  mutant	   (Figure	   14A)	   could	   be	   the	  cause	   of	   the	   missed	   morphological	   rescue	   of	   the	   embryos.	   This	   observation	  corroborates	  the	  hypothesis	  that,	   in	  a	  model	   in	  which	  HDAC2	  is	  not	  present,	  even	  a	  difference	  of	  40%	   in	   the	  deacetylating	  ability	  of	   the	  enzyme	   is	  able	   to	   substantially	  affect	  the	  development	  of	  the	  embryos.	  Conversely,	  we	  observed	  that	  overexpression	  of	   hHDAC1	   wt	   or	   its	   Aurora	   phospho	   mutants	   does	   not	   affect	   endogenous	   hdac1	  protein	   levels	  nor	   the	  development	  of	   the	   embryos,	   ruling	  out	   a	  possible	  dominant	  negative	  role	  for	  the	  injected	  constructs	  (Figure	  21).	  	  	  Moreover,	   we	   assessed	   that,	   in	   zebrafish,	   the	   orthologs	   of	   human	   Aurora	   kinases	  phosphorylate	  hHDAC1	  wt	  specifically	  in	  prophase,	  according	  to	  the	  data	  collected	  in	  mammalian	   cells,	  whereas	   the	   injection	   of	   hdac1	  MO	  alone	   or	   plus	   hHDAC1	   S406A	  phospho-­‐null	  mutant	  prevents	  the	  phosphorylation.	  On	  the	  contrary,	  injection	  of	  the	  hHDAC1	   S406E	   mutant	   in	   hdac1	   MO	   background	   mimics	   the	   phosphorylation	   in	  every	  cell	  expressing	  the	  construct	  (Figure	  20).	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Our	  FACS	  analyses	  on	  cells	  of	  heads	  from	  control	  and	  injected	  embryos	  at	  24,	  48	  and	  72	   hpf,	   perfectly	   reflected	   what	   observed	   with	   the	   rescue	   experiments.	   Indeed,	  expression	  of	  the	  human	  HDAC1	  wild	  type	  is	  able	  to	  recover	  the	  correct	  progression	  of	   the	   cell	   cycle	   in	   the	  morphants	   embryos,	  while	   the	  phospho-­‐mimetic	   S406E,	   like	  hdac1	  morpholino,	  leads	  to	  a	  strong	  reduction	  in	  the	  G2-­‐M	  cell	  population	  in	  heads	  of	  developing	  morphants	  (Figure	  22).	  This	  is	  consistent	  with	  the	  striking	  developmental	  defects	   gathered	   from	   morphological	   analysis.	   Instead,	   the	   phospho-­‐null	   S406A	  mutant	   causes	   depletion	   in	   the	   number	   of	   G2-­‐M	   cells	   as	   well,	   but	   only	   within	   a	  defined	   temporal	   window	   (up	   to	   48	   hpf),	   thus	   leading	   to	   a	   developmental	   delay	  rather	  than	  to	  morphological	  defects.	  	  It	  was	  recently	  shown	  that	  also	  Aurora	  kinase	  B	  phosphorylates	   class	   II	  HDAC	  4,	  5	  and	  9	  during	  mitosis	   [197].	  This	   finding	  and	  our	  results	  with	  HDAC1	  demonstrate	  that	  Aurora	  kinases	  are	  crucial	  regulators	  of	  HDACs	  during	   the	   cell	   cycle	   and	   that	   different	   classes	   of	  HDACs	   are	   important	   in	   different	  phases	  of	  the	  mitosis:	  class	  I	  HDAC1	  in	  prophase	  and	  early	  mitosis,	  class	  II	  HDACs	  in	  late	  anaphase	  and	  mitotic	  exit.	  Many	   papers	   reported	   increased	   histone	   acetylation	   in	   zebrafish	   embryos	   upon	  treatment	   with	   the	   HDAC1	   inhibitor	   TSA	   [198,199]	   or	   following	   hdac1	   depletion	  [109,112].	  Our	   IHC	  experiments	  with	  hdac1	  MO	   reproduced	   these	  data	   (Figure	  23)	  and	   the	   co-­‐injection	   of	   hdac1	  MO	   together	   with	   the	   two	   Aurora-­‐phospho	  mutants,	  additionally	   suggest	   that	   Aurora-­‐dependent	   phosphorylation	   of	   HDAC1	   regulates	  global	   histone	   acetylation	   levels	   in	   developing	   zebrafish	   embryos.	   It	   is	   also	   worth	  noticing	   that	  our	   in	  vivo	  findings,	   in	  which	  expression	  of	  hHDAC1	  S406E	   into	  hdac1	  MO	  background	  does	  not	  rescue	  the	  enhanced	  histone	  acetylation	  levels	  compared	  to	  control	   embryos	   (Figure	   23),	   is	   in	   line	  with	   the	   in	  vitro	   evidence	   on	   the	   decreased	  deacetylating	  activity	  of	  the	  S406E	  HDAC1	  mutant	  is	  in	  zebrafish	  embryos.	  These	  data	  suggest	   that	   the	   Aurora	   phospho-­‐mimetic	  mutant	   is	   not	   able	   to	   restore	   the	   effects	  
	  84	  
caused	  by	  endogenous	  hdac1	  depletion,	  whereas	  hHDAC1	  wt	  completely	  rescues	  the	  acetylation	  pathway	  when	   injected	   in	  an	  hdac1	  MO	  background.	  On	  the	  other	  hand,	  the	  S406A	  HDAC1	  mutant	  shows	  an	   intermediate	  phenotype,	  which	  contradicts	  our	  working	  model.	  Indeed,	  according	  to	  the	  activity	  assay	  we	  demonstrated	  that	  Aurora	  kinases	   inhibit	   HDAC1	   deacetylating	   potential.	   Hence,	   the	   abolition	   of	   the	   Aurora-­‐mediated	  phosphorylation	  should	  lead	  to	  a	  higher,	  or	  at	  least	  comparable	  to	  HDAC1	  wt,	  deacetylating	  activity	  of	   the	  enzyme.	  One	  possible	  explanation	  could	  be	   that	   the	  persistent	  deacetylase	  activity	  of	  HDAC1	  could	  cause	  a	  secondary	  effect	  and	  activate	  HAT	   (histone	   acetyltransferase)	   enzymes	   to	   compensate	   the	   presence	   of	   HDAC1	  S406A	  mutant.	   Thus,	   the	   immunohistochemistry	   experiments	   must	   be	   repeated	   to	  verify	  this	  hypothesis	  and	  confirm	  our	  preliminary	  data.	  Our	  ChIP	  experiments	  start	  to	  provide	  a	  further	  understanding	  on	  the	  comprehension	  of	   the	   HDAC1	   Aurora-­‐dependent	   phosphorylation	   biology.	   They	   show	   that	   HDAC1	  epigenetically	  modulates	   histones	   acetylation	   levels	   of	   some	   genes	   involved	   in	   the	  zebrafish	   CNS	   development.	   Harrison	   and	   colleagues	   proved	   that	   in	   developing	  zebrafish	   embryos	   expression	   of	   genes	  mainly	   involved	   in	   the	   development	   of	   the	  CNS	  changes	  upon	  hdac1	  ablation	  [112].	  Here	  we	  reported	  that	  in	  the	  representative	  set	  of	  genes	  considered,	  the	  expression	  of	  hHDAC1	  wt	  in	  the	  hdac1	  MO	  background	  is	  able	   to	   bring	   their	   promoter	   acetylation	   levels	   to	   values	   comparable	   to	   those	   of	  control	  embryos.	  Conversely,	  the	  expression	  of	  hdac1	  MO	  plus	  hHDAC1	  S406A	  leads	  to	  a	  reduced	  promoter	  acetylation	  of	  certain	  genes	  (Trim9,	  Pck1),	  but	  not	  of	  others	  (Phlda3,	   Inpp5ka),	   suggesting	   that	   the	   developmental	   delay	   observed	   through	   the	  morphology	   experiment	   is	   probably	   due	   to	   an	   altered	   acetylation	   pathway	  exclusively	   in	   some	   genes,	   whereas	   upon	   co-­‐injection	   of	   hdac1	   MO	   and	   hHDAC1	  S406E	   mutant	   a	   total	   impairment	   takes	   place	   and	   the	   H3K27	   acetylation	   levels	  remain	   highly	   similar	   to	   those	   of	   hdac1	  MO	   (Figure	   24).	   These	   preliminary	   results	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furnish	   a	   better	   explanation	   of	   the	  mechanism	  of	   action	   that	   leads	   to	   a	   differential	  global	  histone	  acetylation	  upon	  injection	  of	  the	  Aurora	  phospho	  mutants,	  but	  need	  to	  be	  further	  confirmed	  by	  the	  expression	  analysis	  of	  the	  genes	  considered.	  Our	  working	  hypothesis	  is	  the	  following:	  as	  cells	  progress	  from	  G2	  to	  metaphase,	  they	  need	  to	  condense	  their	  chromatin,	  monitor	  the	  process	  and	  correct	  any	  abnormalities	  in	   chromatin	   architecture.	   HDAC1	   have	   an	   important	   role	   in	   this	   process	   since	  deacetylation	   of	   key	   residues,	   such	   as	  K9	   of	   histone	   3,	   is	   a	   prerequisite	   for	  mitotic	  DNA	   condensation,	   but	   at	   a	   certain	   point	  HDAC1	   activity	  must	   be	   stopped	   and	   the	  enzyme	   displaced	   from	   chromatin.	   This	   could	   be	   achieved	   through	   Aurora-­‐driven	  phosphorylation	  of	  HDAC1,	  which	  partially	  reduces	  its	  catalytic	  activity.	  	  According	   to	   our	   results,	   Aurora	   kinases	   phosphorylate	   HDAC1	   in	   prophase,	   right	  after	  cells	  enter	  mitosis.	  Thus,	  we	  hypothesized	  that	  this	  phosphorylation	  leads	  to	  a	  decrease	   in	   the	  deacetylating	  potential	  of	   the	  enzyme	  and	  has	  an	  effect	  on	  different	  levels:	  1)	  epigenetically,	  modulating	  histones	  acetylation	  and	  2)	  on	  proliferation	  level,	  controlling	  proper	  cell	  cycle	  progression.	  	  	  In	   physiological	   conditions,	   S406	   HDAC1	   phosphorylation,	   even	   though	   very	  dynamically,	  results	  in	  increased	  promoter	  acetylation	  of	  genes	  expressed	  in	  the	  CNS	  or	   with	   CNS-­‐oriented	   functions,	   thus	   enabling	   an	   accurate	   embryos’	   development.	  Thereafter,	   the	   prompt	   removal	   of	   phosphate	   group	   brings	   promoters’	   acetylation	  levels	  back	  to	  their	  basal	  state.	  In	  more	  exacerbated	  conditions,	   i.e.	  mimicking	  HDAC1	  phosphorylation,	  the	  enzyme	  is	   constitutively	   less	   active;	   thereby	   the	   promoters	   of	   above	   mentioned	   genes	   are	  highly	   acetylated.	   This	   situation	   lasting	   for	   quite	   a	   long	   time	   causes	   an	   overall	  morphological	   impairment	  and	  most	   importantly	  does	  not	  allow	  cells	   to	  go	  through	  mitosis	  provoking	  a	  decrease	  in	  the	  G2/M	  population.	  On	  the	  contrary,	  the	  absolute	  abrogation	  of	   the	  HDAC1	  Aurora-­‐dependent	  phosphorylation	  does	  not	  affect	  proper	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